Institutional Review Board (IRB)

POLICIES AND PROCEDURES MANUAL

IRB #1: Lubbock/Odessa
IRB #2: Amarillo/Dallas
IRB #3: El Paso
IRB #4: El Paso

Effective Date:
11/01/2011
Table of Contents

1.0 INTRODUCTION

2.0 ABOUT THE INSTITUTIONAL REVIEW BOARDS

2.1 Purpose of the Institutional Review Boards
2.2 Principles Governing the IRB
2.3 IRB Scope and Authority
2.4 Federal Regulations and TTUHSC Policy
2.5 TTUHSC Institutional Official and Reporting Procedures
2.6 Composition of IRB
2.7 Selection of IRB Members
2.8 Removal of IRB Members
2.9 IRB Member Training Requirements
2.10 Convened Meetings of the IRB
2.11 Research conducted at more than one site by a single PI
2.12 Research conducted at more than one site by multiple PIs
2.13 Designating TTUHSC as an IRB
2.14 Records and Confidentiality
2.15 IRB Office Records
2.16 Investigator's Research Records
2.17 Submission to an External IRB
2.18 Research conducted by students/residents
   with IRB approval from another institution
2.19 Collaboration between TTUHSC and TTU Researchers

3.0 INVESTIGATOR REQUIREMENTS

3.1 Faculty Status
3.2 TTUHSC Employment Status and IRB Use
3.3 Good Clinical Practice
3.4 Notice of Absence
3.5 Conflict of Interest
3.6 Responsibility for Research Activities
3.7 Clinical Trial Registration
3.8 Principal Investigator and Staff Education Requirements

4.0 LOCAL RESEARCH CONTEXT

5.0 IRB SUBMISSIONS

5.1 Submission Mechanism
5.2 Submission Screening
5.3 Definition of Human Research
5.4 Types of Research Review
5.5 Fee Policy for Industry-Sponsored Applications
5.6 IRB Relation to Other Committees

6.0 EXEMPT STUDIES

7.0 EXPEDITED REVIEW
19.4 Children and Minors 60

20.0 DATA SAFETY MONITORING BOARD/ MONITORING COMMITTES 63

21.0 GENETIC RESEARCH 64
   21.1 Genetic Information Nondiscrimination Act (GINA) 65

22.0 HUMAN BIOLOGICAL SPECIMENS 66
   22.1 Prospective Collection and Use of Human Specimens 66
   22.2 Use of Existing Biological Specimens 66
   22.3 Special Categories of Biological Specimens 67

23.0 CERTIFICATES OF CONFIDENTIALITY 68

24.0 INTERNATIONAL RESEARCH 69

25.0 HUMAN IMMUNODEFICIENCY (HIV) REPORTING 70

26.0 RESEARCH COMPLIANCE 71
   26.1 IRB Authority 71
   26.2 Monitoring and Audits 71
   26.3 Research Without IRB Approval 72
   26.4 External Audits 72

APPENDIX A—GLOSSARY OF TERMS 73

APPENDIX B—ORGANIZATIONAL CHART 81
1.0 INTRODUCTION

The Institutional Review Board (IRB) Policies and Procedures Manual provides the Texas Tech University Health Sciences Center (TTUHSC) research community with an overview of the federal regulations and TTUHSC policies that govern the conduct of research involving human subjects.

There are four registered TTUHSC IRBs:

- IRB #1 Lubbock (ID #IRB00000096) (Reviews projects submitted by investigators from Lubbock and Permian Basin)
- IRB #2 Amarillo (ID #IRB00000097) (Reviews projects submitted by investigators from Amarillo, Dallas, Abilene)
- IRB #3 Paul L. Foster School of Medicine at El Paso (ID #IRB00000098)
- IRB # 4 Paul L. Foster School of Medicine at El Paso (ID # IRB00007656)

Each IRB may also be referred to as “local IRB” in the context just enumerated.

The IRB Policy and Procedures Manual will be revised and updated as new guidance, clarifications, and other information become available. The TTUHSC IRBs will work with all investigators to assist them in adhering to current policies and procedures. Applications approved under any version of the Policies and Procedures may require modifications as federal, state, and local rules change.

Access to Documents

Certain IRB documents are privileged and confidential Medical Committee records, not subject to disclosure except to authorized TTUHSC representatives, including IRB members, TTUHSC Compliance personnel, TTUHSC Research Integrity Office (RIO) staff, the Executive Vice President for Research (EVPR), Associate Vice President for Research (AVPR) and federal regulatory officials. The IRB Office shall make its records accessible for inspection and copying by the authorized entities named above. Requests for authorization to access IRB records shall be made to the Director of the RIO.
2.0 ABOUT THE INSTITUTIONAL REVIEW BOARDS

2.1 Purpose of the Institutional Review Boards

The TTUHSC mission includes conducting research. TTUHSC has an approved, signed Federalwide Assurance (FWA00006767) filed with the Department of Health and Human Services (DHHS). The FWA is TTUHSC’s assurance of compliance that all research involving human subjects will be conducted in accordance with the ethical principles of the Belmont Report and DHHS regulations at 45 CFR 46. Although the assurance applies only to federally funded research, the regulations under 45 CFR 46, including all Subparts, provide the practical basis for the review and approval of all human research at TTUHSC, regardless of funding source.

As set forth in the FWA, TTUHSC has four (4) registered Institutional Review Boards (IRBs) whose purpose is to protect the rights and welfare of human subjects participating in research activities conducted at TTUHSC and any other entity for which TTUHSC has been designated as the IRB of record in the FWA and by written agreement between the parties. These IRBs provide initial and continuing review of research applications and protocols involving human subjects.

Each IRB shall uphold the TTUHSC FWA as filed with OHRP. Each IRB has been registered with DHHS as reviewing both OHRP and FDA-regulated research. Any research subject to the regulations of the Food and Drug Administration (FDA) will be conducted in accordance with those regulations (21 CFR Parts 50, 56, 312, 612, and 812).

Designation of additional IRBs under the Assurance requires prior notification of and approval by OHRP.

The definition of research for the purposes of the IRB may be found at http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html

Please see Section 5.3 for examples of projects that may or may not be considered research projects involving human subjects.

2.2 Principles Governing the IRB

The TTUHSC IRBs are guided by ethical principles applicable to all research involving humans as subjects as set forth in the report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (entitled: Ethical Principles Guidelines for the Protection of Human Subjects of Research, known as the “Belmont Report”). The ethical principles set forth in the Belmont Report are:

- **Respect for Persons**: recognition of the personal dignity and autonomy of individuals and special protection of those persons with diminished autonomy;
- **Beneficence**: obligation to protect persons from harm by maximizing anticipated benefits and minimizing possible risks of harm; and
- **Justice**: fairness in the distribution of research benefits and burdens.
2.3 IRB Scope and Authority

Only research using human subjects requires IRB review. Researchers who are unsure if their research falls into this category should consult the decision tree found at http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html or contact their local IRB office. Research using unidentifiable publicly or commercially available databases, human cell lines or material from human cadavers does not require submission to the IRB for review or exemption. Data that had previously been collected for an IRB-approved research project may be re-analyzed to answer a new research question ONLY if the data have been completely de-identified prior to the new analysis. Any other research involving these data requires a new IRB submission prior to their use. See also Section 5.3 and Section 23.0 for additional discussion.

All human research which is exempt under section 45 CFR 46.101(b)(1-6) will be conducted in accordance with TTUHSC policies and procedures. Federal regulations do not permit an investigator to determine whether proposed research is exempt from the Common Rule. The decision as to whether a particular research project is exempt is a decision made by the IRB. Therefore, requests for exemption from formal IRB review are to be made to the local IRB Office via iRIS.

Research involving human subjects (regardless of sponsorship) and all other activities that involve such research in any way must be reviewed and approved by the IRB if one or more of the following apply:

• The research is sponsored by TTUHSC (unless this is the only connection to TTUHSC);
• The research is conducted by or under the direction of any employee or agent of TTUHSC in connection with his or her responsibilities to TTUHSC;
• The research takes place at any property or facility of TTUHSC;
• The research involves the use of non-public information maintained by TTUHSC;
• The research is conducted in accordance with an assurance filed with the Office for Human Research Protections in which a TTUHSC IRB is designated as the IRB of record and has a signed agreement with TTUHSC:
• Any employee or student of TTUHSC is engaged in the research in connection with his or her responsibilities to TTUHSC.

If the TTUHSC involvement in the research is ONLY to provide information about a study to a potential subject (when ALL research activities are conducted elsewhere, by non-TTUHSC-affiliated research personnel) review and approval by a TTUHSC IRB is not required. The local IRB office, may, however, request a copy of the IRB approval letter from the institution where the research is taking place.

TTUHSC retains the right to designate another entity’s IRB as the reviewer of specified TTUHSC studies. All reviews of designated research will take place in accordance with OHRP guidance and TTUHSC policies and procedures.

The IRB has the authority to approve, require modifications in, or disapprove all research activities that fall within its jurisdiction as specified by federal regulations (45 CFR 46.109; 21 CFR 56.109) and TTUHSC policy. Research that has been reviewed and approved by the IRB may be subject to review and disapproval by TTUHSC officials. However, as stated in 45 CFR 46.112 and 21 CFR56.112, TTUHSC officials may not approve research if it has been
disapproved by a TTUHSC IRB.

2.4 Federal Regulations and TTUHSC Policy

All research involving human subjects conducted at or in affiliation with TTUHSC shall be conducted in accordance with federal regulations and TTUHSC Operating Policy (HSC OP 73.06, 10.16). Applicable federal regulations (as specified in the Code of Federal Regulations, CFR) include, but are not limited to:

- 45 CFR 46, generally known as the Common Rule, and subparts B, C, & D
- 21 CFR 50, Human Subject Protection (Informed Consent)
- 21 CFR 56, Institutional Review Boards,
- 21 CFR 312, Investigational New Drug Application,
- 21 CFR 812, Investigational Device Exemptions.

Any changes made to these rules will be immediately adopted by all TTUHSC IRBs, supplanting anything written in the TTUHSC Policies and Procedures.

2.5 TTUHSC Institutional Official and Reporting Procedures

The Executive Vice President for Research (EVPR) is the TTUHSC Institutional Official with overall responsibility for the TTUHSC IRBs (see TTUHSC OP 73.06, FWA00006767); the TTUHSC Research Compliance Program; and the Research Integrity Office (RIO) (see TTUHSC OP 10.16). The EVPR has access to the iRIS program, which contains all documents, correspondence, and deliberations regarding each protocol reviewed by one of the TTUHSC IRBs. This access permits review of all activities of the TTUHSC IRBs as well as review of all documents submitted for review.

The Chair or authorized designee of each TTUHSC IRB shall have signatory power for review and actions taken by each local IRB. Electronic documents found in iRIS—including all finalized IRB minutes, stamped documents, documents referenced in electronic letters, and official correspondence --have the full approval of the IRB chair/designee and have the authority of signed documents. Handwritten signatures of the IRB Chair/designee are not required under this policy. (See also Section 5.1).

IRB minutes in iRIS are not official until they have been approved by the full board of the IRB.

Research Integrity Office (RIO)

The Senior Director of RIO answers to the EVPR and is responsible for the oversight and direction of the human research protection program at TTUHSC which includes IRB administration, the Research Compliance Program, and TTUHSC human research educational requirements.

Reporting Procedures

IRB Chair(s) shall promptly report pertinent information in writing to the EVPR or other designated TTUHSC officials through the RIO as necessary to facilitate compliance with federal regulations and TTUHSC policy, including the IRB Policies and Procedures.

Pertinent information requiring prompt reporting to the EVPR includes but is not limited to:

- Injuries, unexpected serious harm to subjects or others, or any other unanticipated
problem involving risks to human subjects or others arising from research;
• Any serious or continuing noncompliance with regulations or IRB policies,
  procedures, and determinations;
• Any suspension/termination of IRB approval of research.

The EVPR is responsible and has signatory authority for reporting to external organizations
and/or governmental agencies as required under Federalwide Assurance and TTUHSC policy.
The initial report must take place promptly after all circumstances have been determined. When
possible, corrective actions required by the IRB will be included in the written correspondence to
the external organizations/governmental agencies.

Copies of correspondence with governmental agencies and/or external organizations will be
maintained in the office of the EVPR; copies may also be maintained in the Research Integrity
Office (RIO) and the local IRB office.

2.6 Composition of IRB Committees

General information
The membership requirements of each IRB will be consistent with the requirements indicated in
45 CFR 46.107 and 21 CFR 56.107. Each IRB shall be comprised of at least five members.
The Board must include at least one member whose primary interests are in a scientific area,
one member whose primary interests are in a non-scientific area, and at least one member who
is not affiliated with TTUHSC (i.e. not a family member or spouse of an employee). In order to
achieve quorum, at least one member present must be a non-scientist.

In addition, each TTUHSC IRB is encouraged to include at least one member who is an
attorney. The attorney shall serve as a voting member if s/he is not employed by TTUHSC.
Attorneys that are employed by TTUHSC may not vote nor be considered in determining
quorum. TTUHSC attorneys may participate in all discussions and remain in the meeting while
protocols are being voted upon, however must leave the meeting if a conflict of interest arises.

Consideration must be given to the inclusion of members with diverse backgrounds including
experience in areas involving vulnerable subject populations. A TTUHSC IRB that serves as
the IRB of record for non-TTUHSC entities may appoint a representative from each affiliate, but
is not required to do so. If a representative is appointed from an affiliate, the representative will
be a full IRB member who may vote and be counted toward the quorum. If an IRB is reviewing
a protocol that is outside the level of expertise of IRB members, an expert consultant may be
requested to assess the protocol and present findings, written and/or orally to the IRB. The
consultant is not counted toward quorum and must leave the meeting during the final discussion
and vote on the protocol.

Alternates
Formally appointed alternates should have backgrounds and/or knowledge similar to those
whom they are replacing. Alternates may vote in place of an absent or excused regularly
appointed member. Alternates may attend all meetings; however, their votes are counted only
in the absence of the regularly appointed member. Meeting minutes must indicate when an
alternate member replaces the appointed member.

Qualifications of IRB Members
As specified in 45 CFR 46.107 and 21 CFR 56.107 IRB membership must be (i) sufficiently
qualified through the diversity of the members, including consideration of race, gender, and
cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect
for its advice and counsel; and (ii) able to ascertain the acceptability of proposed research in
terms of Institutional commitments and regulations, applicable law, and standards of
professional conduct and practice. Composition of the membership of the IRB must be
adequate in light of the anticipated scope of activities, the types of subject populations likely to
be involved, and the size and complexity of the entity.

2.7 Selection of IRB Members

All IRB members, including each Chair, shall be appointed by, serve at the discretion of, and
report to the EVPR. Recommendations for appointees may be made to the EVPR by the IRB
chairs, by current IRB members or administrators, or through self-referral. In general, the EVPR
appoints all members effective September 1 of each year. Appointments during other times of
the year are made as necessary to replace members leaving the Board or to add additional
board members and/or alternates. Unless otherwise specified, terms expire on August 31 of the
specified year. Each IRB member will be designated as fulfilling one or more of the following
roles:

1. Scientist
2. Non-scientist
3. Unaffiliated member
4. Prisoner Representative
5. Other

2.8 Removal of IRB Members

Appointment to the IRB may be rescinded at the sole discretion of the EVPR. Removal of
members will generally be for cause but not, in any case, for purposes of retaliation or for
unconstitutional reasons.

2.9 IRB Member Training Requirements

Necessary Documentation: All new IRB members must provide their local IRB office with the
following:

• A current curriculum vita or equivalent
• Evidence of completion of required training
• A signed copy of the IRB Member Agreement
• A completed Financial Disclosure Form (TTUHSC OP 73.09, Attachment A)

New Member Orientation: New IRB members are required to attend an orientation session prior
to participating as a voting member on the IRB. This training is conducted by the IRB
Administrator or designee. Additionally, new members are encouraged to attend and observe a
Board meeting prior to beginning their appointment.

The orientation session is designed to provide education on the following topics:

• Responsibilities and obligations of IRB members;
• Interaction between the IRB Office and the Board;
• Effective meeting skills;
• Terms and regulations (FDA, OHRP, NIH, TTUHSC, etc.);
• Meeting basics (quorum, voting procedures, acceptable templates, etc.);
• Vulnerable populations;
• Liability issues; and
• The use of the iRIS software system for reviewing IRB submissions.

Reference materials provided to new IRB Members include:

• The Belmont Report;
• 45 CFR 46;
• FDA 21 CFR 50, 56;
• Glossary of Terms;
• Local IRB Member Roster and IRB Office Roster;
• Investigator’s Handbook; and

All new IRB members are all required to successfully complete TTUHSC IRB mandatory training.

Continuing Education:
IRB members are encouraged to participate in at least six (6) hours of continuing education annually on the protection of human research subjects. The EVPR will be kept aware of the continuing education opportunities made available to IRB members. Engaging in any of the following is considered evidence of continuing education.

• Completion of the “Collaborative IRB Training Initiative (CITI) Protection of Human Research Subjects” administered by the University of Miami. This training is REQUIRED of all IRB members at least once every 3 years.
• Attending educational presentations as part of regularly scheduled IRB meetings, including changes in Federal Regulations, IRB processes, or forms;
• Perusing relevant books, periodicals, or handouts furnished to IRB members;
• Attending TTUHSC training seminars focusing on relevant topics;
• Attending regional or national seminars or conferences which involve discussion of research ethics.

2.10 Convened meetings of the IRB

IMedris (iRIS): All IRB members are assigned privileges within iRIS which provides access to all study documents for all studies submitted for review at the local IRB.

Quorum
A quorum is present when a majority of the appointed voting members (or their alternates) of the IRB are present and the requirements of the Common Rule are met. The quorum must include at least one member whose primary concerns are in a non-scientific area. Quorum for convened meetings may include video or teleconferencing, provided that the members participating from remote sites have access to all necessary materials required for review.

The IRB may only review proposed research at convened meetings at which a quorum is present. A quorum is not present when a sitting member must recuse him/herself for any reason and that person was necessary for quorum. No official action may be taken at a meeting where a quorum is not present. Despite the presence of a quorum, no action should be taken at an IRB where the assembled members do not have the expertise to review the proposed research.
**Conflict of Interest**

All TTUHSC IRB members are bound to the policies set forth in TTUHSC OP 52.06 Standards of Conduct and Ethics and TTUHSC OP 73.09, Conflict of Interest in Research. Unaffiliated members of the IRB, while not specifically mentioned in these policies, are also bound by the policies and are requested to report financial disclosures at least annually, in accordance with HSC OP 73.09. Failure of any IRB members to comply with these policies may result in suspension of membership by the EVPR. An IRB member may not participate in the initial or continuing review of a project in which the member has a conflicting interest except to provide information requested by the IRB.

IRB members shall recuse themselves from the meeting during the final discussion and vote on research in which any conflict exists, and such shall be noted in the IRB meeting minutes. A conflict may include, but is not limited to:

- A financial conflict of interest through ownership of stock of the sponsor of the research or by an equity position of unknown value.
- Involvement in the research as Principal Investigator (PI), sub-investigator, consultant, etc.
- A personal relationship with the PI (such as a spouse) or strong positive or negative interactions that may be perceived as a possible conflict.
- A personal belief system that would preclude acceptance of any research in that area even though permitted under existing regulations or policies.

**Guests/Consultants at IRB meeting**

Guests or consultants to the IRB may attend the meeting only with advance notice and approval by the Chair and after signing a Confidentiality Agreement prior to the start of the meeting. Persons wishing to attend an IRB meeting as a guest should contact the local IRB Administrator at least one week prior to the meeting.

**Absences**

The importance of IRB member attendance cannot be overstressed. Member absences may affect the quorum and therefore the ability to conduct business. Notification of an expected absence is required. Members absent more than 3 times in a fiscal year may be contacted by the IRB Administrator or IRB Chairperson to confirm their commitment/ability to continue for another fiscal year.

**Investigator Presence During Meeting**

Principal Investigators may be in attendance at an IRB meeting during the summary and general discussion of their protocols in order to provide information and clarification. The IRB may specifically request that the PI be present during discussion at a meeting to address the IRB and/or provide answers to IRB inquiries. The PI will be dismissed during the final discussion and vote. Reviewers are encouraged to contact PI’s prior to the meeting to get questions answered and allow time for changes to the submission to be made.

**IRB and TTUHSC Administrative Staff Members**

IRB or TTUHSC administrative staff members who are not appointed to the IRB but attend IRB meetings by virtue of their position may not be counted toward quorum and do not have voting privileges.

**Meeting Schedule**

Meeting times and locations are located on the relevant IRB website.
IRB members may request that the regularly scheduled meeting date be changed due to conflicts with holidays, faculty meetings, conferences, etc. Changes to the meeting schedule or location of meetings will be communicated to IRB members in a timely manner.

Meeting Minutes
The minutes of all IRB meetings must be in sufficient detail to demonstrate the following:

- Attendance at the meetings and presence of quorum;
- Actions taken by the IRB;
- The vote on each of these actions including (a) members present for the vote (located in the IRB Voting section in iRIS for each submission); (b) the number of members voting for, against, and abstaining;
- The basis for requiring changes in or disapproving initial and continuing research; and
- Thorough discussion of research issues and their resolution.

The IRB meeting minutes must also reflect the following as applicable:

- For research involving pregnant women or and/or fetuses - documentation of IRB findings required under 45 CFR 46 Subpart B;
- For research involving prisoners – presence of appropriate prisoner representative; documentation of IRB findings required under 45 CFR 46 Subpart C;
- For research involving children – documentation of IRB findings in accordance with 45 CFR 46 Subpart D and 21CFR50;
- Consideration of additional safeguards for vulnerable subjects;
- Names of IRB members who abstained from a vote with the reason for abstention; and
- Names of IRB members recused from a discussion/vote due to a conflict of interest and a description of the conflict of interest.

2.11 Research conducted at more than one TTUHSC campus by a single PI

Research that is being conducted at more than one TTUHSC campus may be reviewed only by the IRB of the campus of the PI. However, IRB administrators or members at other campuses involved in the research will be notified that the study is under review so that they may add their own comments to the review. Federal guidelines require that when the IRB is geographically removed from the local research context, the IRB must demonstrate that it has obtained necessary information about the local research context through compliance with established standards (see Section 4.0, Local Research Context).

Occasionally, a researcher will wish to open a research protocol on another campus/site that is already being conducted on the researcher’s home campus. If the research will continue to be conducted under the supervision of the original PI, but on another campus or site, an amendment must be submitted adding the second campus or other site as an additional site.

Alternate sites for research, e.g. doctor’s offices, clinics, etc. may be considered for research when the PI is from TTUHSC or an affiliate for which TTUHSC serves as the IRB. Please consult the local IRB administrator if alternate sites might be used. Alternate sites must be approved by the IRB prior to the initiation of data collection at that site.
2.12 Research conducted at more than one TTUHSC campus by different PIs

If either an external sponsor or the investigator wishes to open a second, independent site for a study that is already open on a campus of TTUHSC with a different PI and a different research team than the original study, the second protocol must be submitted to the local IRB as a new, independent application. OHRP rules do not allow for research protocols, even if they are identical, that are being run by independent research teams to be considered as the same proposal. Each of these open studies must have all amendments, continuing reviews, and other documents submitted separately. Note that the IRB administrators will not routinely communicate with one another regarding these studies.

2.13 Designating TTUHSC as an IRB

Agencies that are unaffiliated with TTUHSC and wish to affiliate with any one of the TTUHSC IRBs must contact the director of the RIO. Prior to submitting any research to a TTUHSC IRB, the agency must:

- Have existing policies regarding the institution’s protection of human subjects
- Have a named Human Research Administrator
- Have an existing Federalwide Assurance (FWA) see: [http://www.hhs.gov/ohrp/assurances/status/index.html](http://www.hhs.gov/ohrp/assurances/status/index.html)
- Have a signed agreement/memorandum of understanding with TTUHSC;
- Have designated the TTUHSC IRB(s) on its FWA.
- Have resources available to conduct proposed research;
- Agree to pay IRB fees upon receipt of invoice.

2.14 Records and Confidentiality

The IRB is a committee of the TTUHSC established for the purpose of carrying out requirements governing research involving human subjects under federal law and TTUHSC policies and procedures. The IRB is a “medical committee” as defined under Texas Health & Safety Code chapter 161, and/or other applicable state and federal statutes. All documents generated by, submitted to, or for the purposes of fulfilling IRB committee duties are confidential and privileged as “medical committee documents.”

2.15 IRB Office Records

File Composition
The IRB Office files shall be maintained, either electronically or on paper, in a manner that reflects a complete history of all IRB actions related to review and approval of a research study, including continuing reviews, amendments, and adverse event reports.

Document Retention
The IRB Office shall retain all IRB paper files for three (3) years after the final expiration date of the research study.

2.16 Investigator Research Records

Every Principal Investigator, whether with TTUHSC or with an affiliated entity, is required by TTUHSC and federal regulations to maintain records of all correspondence relating to the use of human subjects in research. Correspondence with the IRB, notices of approval, and original
signed informed consent documents must be maintained in the PI's records, unless otherwise specified. All records of human subject research are subject to inspection by federal authorities and TTUHSC officials, including but not limited to Research Compliance Officers, the EVPR, and the IRB. All TTUHSC research records (including data) are the property of TTUHSC and shall not be transferred to another entity without prior approval of the EVPR. All researchers must comply with the records retention rules of each sponsoring body or regulatory agency involved in their research.

The conditions for maintaining confidentiality of the subjects and the research records are required for the life of the data. These rules apply equally to any and all research conducted or assisted by students, staff, and faculty.

2.17 Submission to an External IRB

Any designation of an external IRB (another entity’s or independent IRB) as the IRB of record for a TTUHSC research project must be documented by a written agreement between TTUHSC and the external IRB organization. Approval for external IRB review shall be subject to federal regulations and TTUHSC policy. Research meeting the criteria outlined in Section 2.3 will not generally be delegated to an external IRB for review.

2.18 Research conducted by students/residents with IRB approval from another institution

In certain cases, TTUHSC students or residents who are engaging in research projects which have been reviewed and approved by another institution’s IRB may not require separate review by a TTUHSC IRB.

TTUHSC will not generally require a separate review of a study protocol in which a TTUHSC student or resident is involved if all of the following conditions are met:

- The research is being conducted at an institution with an OHRP Federal-Wide Assurance.
- All research activity will occur at the other site. No research activity will be taking place at TTUHSC or at an institution affiliated with a TTUHSC IRB.
- A principal investigator from the other institution will be responsible for oversight of the project.
- The student/resident is listed as research personnel on the IRB-approved protocol at the research site.
- TTUHSC is not the recipient of funding for the research project.

If any of the conditions above is not met, the project will require review and approval by a TTUHSC IRB as well as the other institution’s IRB prior to the student/resident’s involvement in the project.

If all of the conditions are met, the student/resident involved in the project will be responsible for providing a copy of the IRB approval letter (and approved informed consent document, if applicable) to his or her TTUHSC IRB Office. TTUHSC reserves the right to limit, suspend or terminate the involvement of TTUHSC students or residents in studies approved by another institution’s IRB.
2.19—Collaboration between TTUHSC and TTU researchers

Research being conducted jointly by faculty at TTUHSC and Texas Tech University campuses (TTU) may be reviewed by a single IRB. The two institutions have entered into an agreement such that, in general, collaborative research conducted using healthy volunteers or persons receiving treatment at the TTU Psychology Clinic or TTU Counseling Center will generally be reviewed by the TTU IRB. Collaborative research conducted using volunteers with a diagnosed medical condition (requiring the use of medical records) will generally be reviewed by the TTUHSC IRB. Questions regarding which IRB is appropriate for reviewing a particular collaborative project should be directed to the IRB Administrators at TTU or TTUHSC.
3.0 INVESTIGATOR REQUIREMENTS

3.1 Faculty Status

Principal Investigator Eligibility

Principal Investigators from TTUHSC
TTUHSC Principal Investigators (“PI”) must have a TTUHSC faculty appointment (full or part

time) or have a clinical appointment and be doing research as part of their employment at
TTUHSC. TTUHSC employees who do not have faculty status (including residents, students,
assistants, fellows, or other individuals receiving training at TTUHSC) cannot be named as PI
for a research study involving human subjects. These individuals may participate in research as
sub-investigators or study personnel. However, the TTUHSC faculty member who is named as
the PI has ultimate responsibility for conducting and overseeing the research. Human subjects’
research conducted by TTUHSC faculty must be reviewed by a TTUHSC IRB and, in most
cases, must use the TTUHSC approved informed consent template.

Principal Investigators from Affiliated Entities
Employees of entities affiliated with TTUHSC may be named as PI in a research study if, at a
minimum, all of the following conditions are met:

- Affiliated entity has a Federalwide Assurance (FWA) approved by DHHS;
- Affiliated entity has designated at least one of the TTUHSC IRBs on its FWA;
- Affiliated entity has a current IRB Agreement/Memorandum of Understanding
  with TTUHSC;
- Principal Investigator submits application and protocol in accordance with
  federal regulations and TTUHSC policy.
- Authorized official from the affiliated entity provides written documentation to the
  local IRB that (1) the official approves the research; (2) the PI has sufficient
  resources to conduct the research; and (3) the PI has the appropriate education
  and experience to conduct the research.
- The PI agrees to comply with the TTUHSC policies and procedures.

The PI may be asked to submit professional qualifications for review and approval to the
TTUHSC EVPR or designee prior to submitting a proposal to an IRB. Researchers should be
aware that they should have malpractice insurance that covers them while they are doing
research.

Principal Investigators who are self-employed or are not employed by an affiliated entity
Generally, TTUHSC IRBs will not encourage unaffiliated investigators or institutions from using
a TTUHSC IRB as the IRB of record for review of their protocols. Persons or entities in this
category may only be considered a PI and use the TTUHSC IRB only if all of the following
conditions apply:

- The affiliated entity has a Federal-wide Assurance approved by DHHS, as well as written
  procedures for protecting the rights and welfare of research participants at the entity.
  These procedures must be submitted for review by a TTUHSC IRB prior to submission
  of a research project.
- The investigator/entity has designated a TTUHSC IRB by executing a written IRB
  Agreement with TTUHSC.
• The investigator/entity has agreed that the TTUHSC Research Compliance Office shall have access upon request to research project records for audit and compliance purposes.

• The investigator possesses a terminal degree, with professional qualifications appropriate for the conduct of the proposed research; The investigator may be requested to submit professional qualifications for review and approval to the TTUHSC EVPR or designee prior to submitting a proposal to an IRB.

• The investigator/entity has resources available to conduct proposed research.

These investigators may not use TTUHSC facilities for conduct of the research. Malpractice coverage is the responsibility of the PI and/or the employing entity. PI shall submit documentation of coverage to RIO at the request of the IRB or TTUHSC.

3.2 TTUHSC Employment Status and IRB Use

TTUHSC faculty employees—full-time and part-time—where research is considered part of the faculty member’s job duties:

• **Must** use the TTUHSC IRB
• Must pay IRB review fees if the study is funded by an industry sponsor.
• Must use the TTUHSC Director of Clinical Contracting to process any Confidential Disclosure Agreements and Clinical Trials Agreements IF the study is funded by an industry sponsor.
• School of Medicine faculty physicians are covered under the TTUHSC Professional Liability Self-Insurance Plan; other HSC schools should check their malpractice policies.
• Employees are covered by the Texas Torts Claims Act if actions are in the course and scope of employment and in good faith.

Note: An Individual Investigator Agreement may be used by a TTUHSC investigator to extend the applicability of the TTUHSC FWA to cover either collaborating investigators for a single protocol. Information regarding this agreement and its use may be found at [http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.html](http://www.hhs.gov/ohrp/policy/guidanceonalternativetofwa.html)

Any Individual Investigator Agreements will originate from the RIO office and be filed there. Contact your local IRB administrator prior to submitting any research that might require this agreement.

Faculty member with a TTUHSC faculty appointment (usually clinical), who is conducting research that is not connected to the TTUHSC appointment. This person is generally self-employed or employed by another entity and not a TTUHSC-compensated employee:

• Must use the TTUHSC IRB if using staff, facilities, or resources of TTUHSC.
• Outside entity must have an executed IRB Agreement or Unaffiliated Investigator Agreement in place to use the IRB.
• Must pay IRB review fees upon receipt of invoice.
• Professional Liability coverage by the TTUHSC Self-Insurance Plan is **not** provided by the TTUHSC Self-Insurance Plan, but the faculty member shall check with their own Professional Liability Plan to confirm coverage.
• Texas Torts Claims Act does not apply (because not an employee, but may apply if performing services under a contract).
Self-employed or employed by another entity without a TTUHSC faculty appointment:

- Can use the TTUHSC IRB only if they:
  a. Have a Federal-wide Assurance approved by DHHS and written procedures for protection of rights and welfare of research participants. Written procedures must be submitted for review to the TTUHSC Research Integrity Office.
  b. Have designated a TTUHSC IRB by executing an IRB Agreement with TTUHSC as applicable.
  c. Have agreed that the TTUHSC Research Compliance Office shall have access upon request to research project records for audit and compliance purposes.
  d. Possesses a terminal degree, with professional qualifications appropriate for the conduct of the proposed research; The investigator may be requested to submit professional qualifications for review and approval to the TTUHSC EVPR or designee prior to submitting a proposal to an IRB.
  e. Have resources available to conduct proposed research;

- Must pay IRB review fees upon receipt of invoice.

- Cannot use TTUHSC on the heading of the consent form or suggest that the research is being conducted, approved, or sponsored in any way by TTUHSC. Any consent form must be approved by the TTUHSC IRB;

- Cannot use TTUHSC facilities for conduct of the research;

- Must provide evidence of malpractice coverage that covers the scope of the research project. Malpractice coverage is the responsibility of the PI and/or the employing entity.

3.3 Good Clinical Practice

Good Clinical Practice (GCP)
Principal Investigators, regardless of their affiliation, shall follow Good Clinical Practice Guidelines as defined by the FDA in designing and conducting clinical trials. GCP guidelines can be found at the following website:

The TTUHSC IRBs will also follow GCP guidelines in the review and approval of clinical trials.

3.4 Notice of Absence

Principal investigators shall notify the IRB in writing as soon as possible prior to any employment change, extended absence, or faculty development leave during which the PI will be engaged in research. (See TTUHSC OP 60.02) PI shall submit information and/or an amendment to the IRB designating an investigator responsible for any active research study during PI’s absence. Notice and/or amendments shall be made in accordance with local IRB submission requirements.

3.5 Conflict of Interest

All TTUHSC investigators and study personnel are bound to the policies set forth in TTUHSC OP 52.06 Standards of Conduct and Ethics, and TTUHSC OP 73.09, Conflict of Interest in Research. Unaffiliated investigators may also be bound to these policies if their own institutions do not have internal conflict of interest policies. Failure of any PIs and their research personnel to comply with these policies may result in suspension of submission privileges. In accordance
with the TTUHSC Conflict of Interest in Research Policy, all research personnel are required to disclose any financial conflicts of interest as outlined in the policy. These disclosures are to be made at least annually, and are to be updated more frequently as circumstances change.

If a project is submitted for IRB review and it is determined that a conflict of interest exists, the issue must be referred to the Conflict of Interest Committee (COIC) established by TTUHSC OP 73.09. The IRB will not continue the review of the submission until the COIC has met and made its recommendations and these recommendations have been forwarded to the IRB by the investigator. Affiliated entities should submit documentation to the IRB specifying the identified conflict of interest and how it will be managed.

3.6 Responsibility for Research Activities

The Principal Investigator retains ultimate responsibility for the conduct of all research activities as specified in the IRB-approved protocol and for submission of all required documents including the application, protocol, forms, responses to stipulations, revisions, reports, and any other documentation, including those made by authorized research personnel in accordance with TTUHSC IRB Policies and Procedures. Ensuring that prompt and proper payment of subjects in accordance with information in the signed informed consent document is also the responsibility of the principal investigator. While duties related to the conduct of the research may be delegated to other members of the research team, the responsibilities of conducting the research remain with the principal investigator.

3.7 Clinical Trial Registration

The sponsor of any clinical trial must register the study on a publicly accessible trial registration site prior to enrolling the first subject. ClinicalTrials.gov is a directory of federally and privately supported research trials designed to test the effect of experimental drugs, devices and procedures for many diseases and conditions. The FDA mandates the registration of clinical trials on the website prior to enrollment of the first participant. Other entities, including NIH, have similar requirements for registration of applicable clinical trials. If an IRB-approved study is a clinical trial which has not been registered by the study sponsor, it may be the Principal Investigator's responsibility to register the trial. The following website provides more information: http://prsinfo.clinicaltrials.gov/. The Director of the RIO serves as the TTUHSC administrator for registration at clinicaltrials.gov. and should be contacted for account set-up.

In addition, FDA regulations (21 CFR 50.25c) requires the following statement in informed consent documents for all applicable clinical trials overseen by the agency: “A description of this clinical trial will be available on http://www.ClinicalTrials.gov as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.” The statement has been included in the TTUHSC biomedical informed consent template.

3.8 Principal Investigator and Research Staff Education Requirements

Initial TTUHSC Training Program
All principal investigators, co-investigators, all research staff, and IRB members from TTUHSC and its affiliates are required to receive initial and continuing training regarding the rights and protection of human subjects in research. The course currently approved by TTUHSC is the web based Protection of Human Subjects administered by the University of Miami through the
Collaborative IRB Training Initiative (CITI). All TTUHSC and affiliate PIs, co-Investigators, all research staff, and IRB members are also required to receive training in the Health Insurance Portability and Accountability Act (HIPAA) as it pertains to research. This training is attached to the end of the CITI course. PIs are responsible to ensure that all personnel associated with human subject research complete the initial training program prior to beginning work on any study. The RIO may also offer additional training on a scheduled basis or as requested by researchers, administrators, or departments.

If applications submitted to the TTUHSC IRBs have co-investigators or research staff from schools or hospitals that are not formally affiliated with TTUHSC, the TTUHSC IRBs retain the right, at their discretion, to request documentation of training regarding the rights and protection of human subjects in research, or, in its absence, require the unaffiliated co-investigators or research staff to take TTUHSC required training prior to final IRB approval. Other forms of human research training may be approved at the recommendation of the IRB Administrator and at the final discretion of the Educational Coordinator. A description of the training and a copy of a completion certificate shall be provided by the Investigator to the Education Coordinator in the RIO. Any Biomedical CITI training that is current within 3 years is acceptable upon receipt of the completion certificate by the Educational Coordinator. In this case additional HIPAA training may be required.

Continuing Education
Investigators and research staff are required to receive continuing education on the protection of human research subjects every three years. The approved course for continuing education is the “Collaborative IRB Training Initiative (CITI) Protection of Human Research Subjects” administered by the University of Miami. This is the same course approved for initial training. The course is updated regularly to reflect changes in the regulatory and research environments. This also fulfills the requirements for continuing education in HIPAA. Questions about continuing education requirements shall be directed to the Educational Coordinator in the RIO.

Additional Educational Resources
The IRB website and iRIS Home Page provide links to additional resources, including TTUHSC’s Assurance, IRB Policy and Procedure Manual, Investigator’s Handbook, relevant conferences, and the Internet Research Information System (iRIS). Books, periodicals and other relevant educational materials are available at all of the IRB offices.
4.0 LOCAL RESEARCH CONTEXT

TTUHSC's responsibilities under its Assurance apply whenever TTUHSC or its employees are engaged in human subjects research which is not otherwise exempt from applicable federal regulations, regardless of the geographic location of the research. This is particularly critical when the research involves greater than minimal risk to subjects or vulnerable categories of subjects.

When the IRB is geographically removed from the local research context, the IRB must demonstrate that it has obtained necessary information about the local research context through compliance with one of the standards below. These standards reflect minimum levels of adequacy. More stringent standards may be required, depending upon the nature of the proposed research or the relevant research context.

a. When the research takes place outside of the TTUHSC geographical area and involves minimal risk to subjects, the IRB shall document in writing that it has obtained necessary information about the local research context through written materials or discussions with appropriate consultants.

b. When the research takes place outside of the TTUHSC geographical area, involves greater than minimal risk to subjects but the local research context involves no intervention or interaction with subjects and the principal risk associated with the local research context is limited to the potential harm resulting from a breach of confidentiality, the IRB shall:

• Document in writing that it has obtained necessary information about the local research context through written materials or discussions with appropriate consultants.

• Determine and specifically document that provisions to protect the privacy of subjects and maintain the confidentiality of data are adequate.

Necessary information under DHHS regulations includes all of the following:

• the anticipated scope of the entity's research activities;
• the types of subject populations likely to be involved;
• the size and complexity of the entity;
• institutional commitments and regulations;
• applicable law;
• standards of professional conduct and practice;
• method for equitable selection of subjects;
• method for protection of privacy of subjects;
• method for maintenance of confidentiality of data;
• language(s) understood by prospective subjects;
• method for minimizing the possibility of coercion or undue influence in seeking consent; and
• safeguards to protect the rights and welfare of vulnerable subjects.

c. When the research takes place outside of the TTUHSC geographical area, is of greater than minimal risk to the subjects, and paragraph “b” above does not apply, the IRB shall document in writing that it has obtained necessary information about the local research context through one or more of the following mechanisms, or through other
mechanisms deemed appropriate by OHRP for the proposed research and the local research context.

(i) Personal knowledge of the local research context on the part of one or more IRB members, such knowledge having been obtained through extended, direct experience with the research entity, its subject populations, and its surrounding community.

(ii) Participation (either physically or through audiovisual conference) by one or more appropriate consultants in convened meetings of the IRB. Such consultant(s) shall have personal knowledge of the local research context, such knowledge having been obtained through extended, direct experience with the research entity, its subject populations, and its surrounding community.

(iii) Prior written review of the proposed research by one or more appropriate consultants, in conjunction with participation (either physically or through audiovisual conference) by the consultant(s) in convened meetings of the IRB, when such participation is deemed warranted either by the consultant(s) or by any member of the IRB.

(iv) Systematic, reciprocal, and documented interchange between the IRB and elements of the local research context. Such interchange may include:

• Periodic visits to the research site by one or more IRB members in order to obtain and maintain knowledge of the local research context, including the research entity, its subject populations, and its surrounding community;
• periodic discussion with appropriate consultants knowledgeable about the local research context;
• regular interaction with one or more of the entity’s designated liaisons; and
• review of relevant written materials.

When relying on another IRB’s review, the TTUHSC IRB has a responsibility to verify in the meeting minutes that the particular characteristics of the local research context are considered, either (i) through knowledge of the local research context by the reviewing IRB (see paragraph 2 above); or (ii) through subsequent review by appropriate designated institutional officials, such as the Chair and/or other members of its local IRB.
5.0 IRB SUBMISSION MECHANISM, SCREENING, DEFINITIONS, FEES, AND RELATIONSHIPS TO OTHER COMMITTEES

5.1 Submission Mechanism

All submissions including initial applications, continuing reviews and amendment requests must be submitted using Internet Medical Research Information System (iRIS) Software. This is also the mechanism through which information is communicated between investigators and the IRB. All correspondence generated by iRIS and sent to research personnel is considered official and does not require the handwritten signature of an IRB Chairperson or designee (See section 2.5).

5.2 Submission Screening

All IRB submissions will be screened by the local IRB Office. If the submission is incomplete or otherwise not fully prepared for review, it will be returned to the PI with a request for correction. If a PI wishes a more extensive screening of an initial review submission by the IRB Administrator; efforts should be made to submit the necessary study documents as much in advance of the IRB submission deadline as possible. When the submission is adequately prepared for review, it will be placed on an agenda for IRB review.

5.3 Definition of Human Research

In order to require IRB review, studies must involve research that uses human subjects. Research is defined as a systematic investigation designed to develop or contribute to generalizable knowledge. For instance, a written report of a single case study is not considered research because it is neither a systematic investigation nor are its results generalizable. However, if a researcher wishes to combine more than one case study to find a common thread, or conduct a retrospective chart review, these activities would involve a systematic investigation looking for generalizable knowledge, and would be considered research.

In order to be considered human research, the study must involve living individuals. Research using commercially sponsored de-identified cell lines or research using cadavers, for example, is not human research and does not have to be submitted to the IRB for either exemption or review. (See Section 23.0) Note that HIPAA requirements differ somewhat in this area. Before submitting an IRB application, Investigators should review HIPAA requirements on research with cadavers.

The federal regulations make no explicit distinction between human research conducted on oneself versus others. Therefore, TTUHSC investigators who intend to conduct research using themselves as a research subject (or intend to use their own tissues or specimens) are expected to submit the project for review and approval by a TTUHSC IRB prior to engaging in the research activity.

Contact the local IRB Administrator if there is any question as to whether or not you are conducting human research.

5.4 Types of Research Review

Three categories of review are recognized by federal regulations. Rules for submission in each
of these categories may be found elsewhere in this manual.

**Exempt**: Research that may be exempted from federal regulation requirements regarding human research by the IRB Chair or designee.

**Expedited**: Research that federal regulations allow the IRB Chair or designee to perform the initial review.

**Full Board**: Research must be reviewed at a convened meeting of the IRB.

### 5.5 IRB Fee Policy for Commercially Sponsored Applications

All commercially sponsored applications submitted to the IRB for initial review will be assessed a fee for new applications and continuing review applications requiring full Board review. The IRB fee and payment schedule shall be determined by the RIO and established during contract negotiations with sponsors and in IRB Agreements with affiliated entities (see: TTUHSC Operating Policy 73.08.)

Currently, the fee for commercially sponsored initial reviews is $2,000. Currently, the fee for commercially sponsored continuing reviews is $750. There is no fee for reviews of amendments to the protocol or adverse events.

If an application is received and is not designated as having a commercial sponsor, but is later determined by the IRB to have a commercial sponsor, an invoice will be sent to the sponsor or affiliated entity. The invoice shall contain a request for billing information and will clearly show a description of the charge and the amount being assessed.

IRB applications supported by State, Federal, non-profit foundation, or internal funds are excluded from this charge.

**Waiver of IRB Fees**

There may be extenuating circumstances where charging IRB fees would be unwarranted. PIs may send a written letter requesting waiver of IRB fees to the EVPR, who has discretion and makes the final decision to waive fees.

### 5.6 IRB Relation to Other University Committees

The TTUHSC IRB functions independently of, but in coordination with other TTUHSC and Texas Tech University Committees, including:

- Institutional Biosafety Committee (IBC)
- Recombinant DNA Biosafety Committee (RDBC)
- Radiation Safety Committee (RSC)
- Conflict of Interest Committee
- Texas Tech University IRB

The IRB may request that approval from any of these committees be obtained prior to TTUHSC IRB approval.
6.0 EXEMPT STUDIES

The determination of whether a TTUHSC study qualifies for exempt status must be made by the Chair of the local IRB or by a person(s) designated by the IRB Chair; TTUHSC researchers may not make these judgments themselves. The designation must be granted prior to the research commencing. IRB approval may never be granted for research already in progress or completed.

If a PI, after reviewing the decision charts found at the OHRP website http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html considers a study to be exempt, only the following documents need be submitted:

- IRB Application indicating the nature of the requested exemption, found in iRIS;
- The full research protocol;
- A HIPAA Waiver (found in iRIS) for studies using protected health information;
- Any other available documentation to help support the application, to include data collection forms, surveys, recruitment letters, etc.

Federal regulations 45 CFR 46.101(b) provide for six specific categories of activities that may qualify as exempt. Exempt status will never apply to research involving prisoners. The exemption categories are summarized below:

- Research conducted in established or commonly accepted educational settings involving normal educational practices
- Research involving the use of educational tests, surveys, or questionnaires, provided that human subjects cannot be identified and that responses by the subjects will not place them at risk of liability or be damaging to financial standing or reputation. An example of a study that might be exempt is one conducting a survey on all graduate students by stopping them in the hallway but not asking for their names or any other identifying information.
- Research involving the use of educational tests or observation of public behavior that is not exempt under the previous category if (1) the human subjects are elected or appointed public officials or candidates for public office or (2) the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.
- Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the PI in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. An example of this category is a retrospective chart review where no identifying information is recorded by the investigator. The exemption must be granted by the IRB office prior to the research taking place. In addition, this category requires that all data are already in existence at the time the application for exemption is made to the IRB.
- Research and demonstration projects which are conducted by or subject to the approval of Federal Department or Agency heads in order to review public service programs; procedures for obtaining benefits under those programs; possible changes to
those programs or possible changes in methods or levels of payment for benefits under those programs.

- Taste and food quality evaluation and consumer acceptance studies.

If the research application does not meet the criteria for exemption, the IRB Office will provide written notice to the PI specifying the additional information needed. The IRB chair/designee retains the right to refer any application for expedited or full board review, even if it appears to meet the qualifications for exemption.
7.0 EXPEDITED REVIEW

An expedited review procedure consists of a review of research involving human subjects by the
IRB Chair or by one or more experienced reviewers designated by the Chair from among
members of the IRB. Federal regulations allow the IRB to review certain applications on an
expedited basis if they meet specified criteria.

Submissions which may receive expedited review will be initially screened by the IRB staff and
assigned to the IRB Chairperson or an experienced IRB member.

In reviewing the research, the reviewer may exercise all of the authorities of the full Board
except that the reviewer may not disapprove the research. Additionally, the reviewer has the
discretion to refer the application for review at a convened meeting of the full Board.

Federal regulations limit the use of expedited review procedures to specific research categories
published in the Federal Register. Expedited review is appropriate for research activities that

* present no more than minimal risk to human subjects, and
* involve only procedures that are listed in one or more of the research categories that
  may be found in OHRP’s policy on categories of research that may be reviewed through
  an expedited procedure. The policy is summarized below and the full text can be found

Categories of Research that may receive expedited review:

1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
   a. (a) Research on drugs for which an investigational new drug application (21 CFR
      Part 312) is not required.
   b. Research on medical devices for which (i) an investigational device exemption
      application (21 CFR Part 812) is not required; or (ii) the medical device is
      cleared/approved for marketing and the medical device is being used in accordance
      with its cleared/approved labeling.

2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
   a. (a) from healthy, nonpregnant adults who weigh at least 110 pounds. For these
      subjects, the amounts drawn may not exceed 550 ml in an 8 week period and
      collection may not occur more frequently than 2 times per week; or
   b. from other adults and children considering the age, weight, and health of the
      subjects, the collection procedure, the amount of blood to be collected, and the
      frequency with which it will be collected. For these subjects, the amount drawn may
      not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may
      not occur more frequently than 2 times per week.

3. Prospective collection of biological specimens for research purposes by noninvasive
   means.
4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)

5. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis).

6. Collection of data from voice, video, digital, or image recordings made for research purposes.

7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.)

8. Continuing review of research previously approved by the convened IRB as follows:
   where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects; or where no subjects have been enrolled and no additional risks have been identified; or where the remaining research activities are limited to data analysis.

9. Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

Approval
In conducting the expedited review, the designated reviewers must review materials in sufficient detail to make the same determinations as specified in the full Board review section.

Notification of Full Board  The project, including all documents and reviewer’s comments will be included in the agenda provided to the full Board for the next convened meeting to allow for member comments. This documentation should cite the specific permissible category or categories justifying the expedited review.
8.0 FULL BOARD REVIEW

Review of research by the full board may occur only at convened meetings of the IRB at which a quorum and at least one non-scientific member of the Board are present. Studies are determined to require full Board review based on the potential level of risk (minimal, greater than minimal) to human subjects as determined by the Chair. Any proposed studies using investigational drugs or devices; approved drugs or devices in unapproved categories will always require full board review. Principal investigators may choose to attend the IRB meeting at which their protocol is being presented in order to answer any questions the members may have.

The full Board review process includes the following components:

- Project will be pre-reviewed by IRB Office staff to ensure that the submission is complete. Note that for more thorough pre-reviews, submissions should be completed well in advance of the IRB deadline.
- IRB Chair or designee shall assign each protocol for review to at least two IRB members, one of whom will be designated the primary reviewer, one the secondary reviewer. Efforts will be made to make assignments primarily on the basis of reviewer expertise. Non-scientist members will not be assigned as primary reviewers. All study materials are routinely available to all IRB members for review through the iRIS system. The primary and secondary reviewers conduct an in-depth review of all materials and enter their comments into iRIS; all IRB members are encouraged to review all submissions and make comments. Reviewers are encouraged to contact PIs prior to the IRB meeting with any questions they have so that these issues may be addressed in advance of the full Board meeting. A summary of the study and recommendations regarding the disposition of the study shall be presented by the primary and secondary reviewers. Clarification and discussion by the full Board then takes place.

- Existence of quorum and at least one non-scientific member of the IRB will be required for any vote by the full board.

  - A majority vote of the voting members is required to formalize IRB decisions.

IRB review will result in one of the following actions:

Approval
The IRB may only approve an application when the requirements for approval stated in 45 CFR 46.111 and, when applicable, 21 CFR56.111 are satisfied. These requirements are summarized as follows:

- Risks to subjects are minimized.
- Risks to subjects are reasonable in relation to anticipated benefits.
- Selection of subjects is equitable.
- Informed consent will be sought from each prospective subject or representative.
- Informed consent will be appropriately documented as required by federal regulation.
- Plans for data monitoring are included when appropriate.
- Adequate provisions are in place to protect the privacy of subjects and the confidentiality of data.
- Additional safeguards have been included to protect the rights and welfare of
vulnerable subjects when necessary.

The Investigator will also be informed that s/he is required to promptly report to the IRB any changes in research activity and any unanticipated problems involving risks to subjects.

**Determination of risk**

IRB members will make a determination of the risk level of a study and the interval between continuing reviews (See Section 14) based on the vulnerability and health of the research participants, the level of innovation involved in the drugs, devices and/or procedures involved in the project, and the likelihood of participants experiencing physical or psychological effects from the administration of study drugs/procedures. Projects reviewed at full board meetings will be assigned both a risk level (minimal risk or greater than minimal risk) and a review cycle at the time that approval of the project is recommended.

**Request Additional Information or Modifications from PI**

The IRB may request clarifications, protocol modifications, revisions to the informed consent document, or other supporting documentation. In iRIS, these requests are generally found in the section entitled “Stipulations”. A stipulation is a request made by a reviewer that must be addressed before an IRB submission can be approved. For each stipulation, the investigator is asked, “Do you accept this stipulation?” The investigator replies “yes” or “no” and provides an explanation of the response. The responses are subsequently reviewed through administrative review if the stipulations involve minor modifications and/or the proposal is eligible for expedited review; or by the full board of the IRB if the proposal initially required full board approval and the modifications are greater than minor. The IRB determines at the original Board meeting whether the modifications are minor.

A minor modification is defined as a change that would not materially affect an assessment of the risks and benefits of the study or does not substantially change the specific aims or design of the study. Examples of minor requested changes may include editorial changes or corrections to study documents, submission of missing documents, or letters of support. Full Board review of the minor requested changes is not necessary.

A major modification may materially affect the assessment of the risks and benefits of the study or may change specific aims or designs of the study. These modifications will require subsequent full board review. Examples of major requested changes may include clarification of study design, methodology, recruitment procedures or changes to inclusion and exclusion criteria.

The PI is requested to address stipulations and/or for additional information in writing in a timely manner following the Board’s decision. Replies are due within 30 days of the date of the written notice to the PI unless otherwise specified. If no response has been received after 30 days, the study may be administratively closed by the IRB and further review of the study will require a new application to be submitted to the IRB.

**Study Tabled**

A study may be tabled under the following circumstances:

- Numerous greater than minor changes required or Incomplete application.
  The IRB has reviewed the study and determined that extensive substantive
changes are necessary before the study can be effectively reviewed. The PI will be notified of the decision and of the corrective action(s) needed before further review can take place. The investigator will have 30 days from the date of notice to respond to the written request for changes. If no response has been received from the PI after 30 days, the study will be administratively closed and removed from the IRB agenda. Further review of the study will require a new application to be submitted to the IRB.

- **IRB members or consultants not available for review**
  The study was unable to be reviewed by the Board for reasons unrelated to the PI. Such reasons may include loss of quorum, unavailability of required member for a thorough review, or the need for outside consultation to assist the IRB. The study will be rescheduled with no action required by the PI.

- **Necessary documentation from other pertinent TTUHSC committees, e.g. Conflict of Interest Committee, has not been provided.** The study will not be rescheduled until all necessary documentation is provided.

**NOTE:** All studies that are tabled at a full Board meeting will require subsequent full Board review unless substantial changes place them in a different category.

**Study Disapproved**

The IRB votes to disapprove a study and determines that there will be no further review of this application.

The IRB shall provide the PI with written notification of the reasons for its decision. The PI may request reconsideration of the IRB’s decision in writing within ten (10) days of the date of notice. The PI shall provide a rationale for the request to reconsider and any other relevant supporting documentation. The PI may also address the IRB in person. The IRB shall notify the PI in writing of its decision after reconsideration and the reasons for its decision. No further request for reconsideration by the PI is permitted following the final decision by the IRB. Pursuant to the regulations in 45 CFR 46.112 and 21 CFR 56.112, TTUHSC officials can **not** approve research if it is disapproved by the IRB.
9.0 INITIAL REVIEW OF APPLICATIONS

TTUHSC PIs shall submit research studies for review to the TTUHSC IRB at the campus of their appointment: Lubbock, Amarillo, or El Paso. This will be the designated IRB for the research activity. Submission of research to the TTUHSC IRB shall be made in accordance with TTUHSC policy and federal regulations. (See TTUHSC OP 73.08 and 73.09).

Non-TTUHSC affiliated PI’s shall submit study documentation for review by the TTUHSC IRB ONLY if TTUHSC is designated as the IRB of record on the entity’s Assurance and has executed an IRB agreement with TTUHSC. Investigators covered by a TTUHSC IRB who are conducting research at a site not affiliated with an Assurance-holding entity must have an executed Unaffiliated Investigator Agreement with TTUHSC to submit research for review by a TTUHSC IRB. PIs wishing an Unaffiliated Investigator Agreement should contact their local IRB administrator.

In conducting the initial review of proposed research, the IRB must obtain information in sufficient detail to make the determinations required under federal regulations. If the designated IRB does not have the expertise necessary to review any study, including those involving a vulnerable population, the IRB Chair may request a review from a consultant or request referral of the study to another TTUHSC IRB for appropriate review, as long as the receiving IRB has an appropriate Institutional Agreement. Federal guidelines require that when the IRB is geographically removed from the local research context, the IRB must demonstrate that it has obtained necessary information about the local research context through compliance with established standards (see Section 4.0 Local Research Context).

The following documents are submitted by the PI, as applicable to the study, for IRB review:

- Completed TTUHSC IRB application form;
- Full protocol;
- Relevant applications or proposals for funding;
- Investigational New Drug (IND) or Investigational Device Exemption (IDE) number (see Section 18.0);
- Investigator’s Brochure (if required);
- Proposed informed consent document using TTUHSC IRB-approved format;
- All proposed data collection forms;
- Authorization to Use and Disclose PHI for Research (HIPAA authorization) and/or Request to Use and Disclose PHI Without Authorization for Research (see Section 11.0);
- Copies of letters of approval or support from non-TTUHSC research sites;
- Recruitment materials;
- Surveys, questionnaires, or videotapes;
- Documentation of review/approval by required TTUHSC institutional committees;
- CV of PI and/or others as requested;
- Other materials as requested.

Materials for initial review shall be submitted to the IRB Office by established deadlines. The deadlines for each TTUHSC IRB, the IRB application forms and other approved form templates can be found on the iRIS homepage.
10.0 INFORMED CONSENT

10.1 The Informed Consent Process

Except in the limited circumstances described below, no investigator may involve a human being as a subject in research covered by these policies unless the investigator has obtained the legally effective informed consent of the subject or the subject’s authorized representative. Authorized study personnel shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and to minimize the possibility of coercion or undue influence. Information regarding the study shall be provided to the subject or representative in language that is understandable to the subject or representative. The process of obtaining informed consent may never include language through which the subject or representative is made to or appears to waive any of his/her legal rights or releases or appears to release the investigator, the sponsor of the study, TTUHSC or its agents from liability for negligence. Investigators should strive to write consent documents in language that would be understandable to a reader with a 7-th grade education.

In limited circumstances, the IRB may alter or waive the requirement for the PI to obtain a signed and dated consent form (see below). Study personnel should contact their local IRB Administrator or the Research Integrity Office if they are unsure of how to obtain legally authorized informed consent. Individual and/or group training will be provided.

The consent form must be written in non-scientific language that is easily understood by all subjects. The non-scientific members of the IRB should be asked to review consents to ensure that they are clear and understandable. All TTUHSC research studies shall utilize one of the TTUHSC Informed Consent templates found in iRIS. These templates include all of the necessary elements of a consent document outlined in 45 CFR 46.116 and 21 CFR 50.25. HIPAA language in the consent form is unnecessary and will not replace the requirement for a separate HIPAA form. A copy of the consent shall be given to the person signing the form. The Principal Investigator shall maintain all original consent documents.

This policy is not intended to limit the authority of a physician to provide emergency medical care, to the extent that the physician is permitted to do so under applicable Federal and State law.

Written Consent Form Signed by Subject or Representative

The PI or designee must provide the opportunity to discuss the informed consent with the subject, reviewing all of the elements, preferably during a face-to-face presentation to the subject or the subject’s representative. The PI shall allow the subject or the representative adequate opportunity to read, review and consider the consent document before it is signed. A signed and dated copy of the document shall be given to the person signing the form. If the subject is an adult but for medical reasons is unable to sign the informed consent, the subject will be asked to sign the informed consent once s/he is physically able. If the subject does not wish to sign the consent, the research will be halted appropriately and, if the subject wishes and it is possible and the consent permits it, the subject’s data will be removed from the research data base. The requirement that the consent be signed may be waived by the IRB on a case-by-case basis following a written request and justification by the investigator.

No Stamped Signatures

The PI (or authorized designee approved by the IRB to obtain informed consent) also signs the consent document at the same time as the subject or representative signs. Stamped signatures
Subjects who do not speak English
These subjects will be presented with an informed consent document written in a language understandable to them. The foreign language version should be a certified translation of the IRB approved English version of the informed consent document. It is, therefore, submitted after the IRB has approved the English version. Certified translations of informed consent documents should be submitted with a certificate verifying the translation was provided by a certified translation service. Certified translations will be acknowledged and stamped by an IRB member or a designee. In cases where a certified translation of the informed consent document has not been provided, the author of the translation and his/her qualifications should be stated/described. Before a non-certified translation is submitted to the IRB, the investigator is responsible for ensuring the accuracy of the translation (by having someone else back-translate the document, for instance). Submission of a non-certified translation may delay the approval of the translated document.

10.2 Altering or waiving the informed consent process

Oral Presentation
In cases where the subject is unable to read the required consent form, the approved consent form may be read to the subject in its entirety in a language understood by the subject or the subject’s representative. A third party witness unaffiliated with the research study will be present during the reading and will be required to sign and date the consent form as a witness to the consent procedure. (See also Section 11.0 HIPAA requirements).

A short form written consent document stating the elements of informed consent required by 45 CFR 46.117 and 21 CFR 50.27(b) may be presented orally to the subject or subject’s representative. When this method is used there shall be a third party witness and the IRB must approve a written summary of what is to be said to the subject or subject’s representative. The subject or subject’s representative shall sign the short form but the witness shall sign the copy of the summary and the short form. The person obtaining the consent shall sign the summary. A copy of the summary and short form shall be provided to the subject or subject’s representative.

Waiver of the Informed Consent Process
The IRB may approve a process which waives the requirement to obtain informed consent provided that the IRB finds and documents the following, in accordance with 45 CFR 46.116(d):
(a) The research involves no more than minimal risk to the subjects;
(b) The waiver will not adversely affect the rights and welfare of the subjects;
(c) The research could not practicably be carried out without the waiver;
(d) When appropriate, the subjects will be provided with pertinent information after participation.

An investigator who requests a waiver of informed consent for a project will include a justification of the four requirements presented here in his/her initial application for IRB review. The request will be reviewed, and, if approved, will be documented in the IRB meeting minutes and on the IRB approval letter. Expedited review of requests to waive the informed consent process is permitted.

Waiver of Documentation of Informed Consent
The IRB may waive the requirement for the PI to obtain a signed consent form for some or all
subjects if it finds that
(a) the only record linking the subject and the research is the consent document AND that the principal risk is the potential harm resulting from a breach of confidentiality;

OR
(b) that the research presents no more than minimal risk of harm to subjects AND does not involve procedures for which written consent is normally required outside of the research context

In cases in which the documentation of consent requirement is waived, the IRB may require the PI to provide subjects with a written statement regarding the research. Investigators wishing to waive the documentation of informed consent for a project must include a justification for the request in their initial application for IRB review. The request will be reviewed, and, if approved, will be documented in the IRB meeting minutes and on the IRB approval letter. Expedited review of requests to waive documentation of informed consent process is permitted.

Exception from informed consent requirements for emergency research
The IRB may approve a research project without requiring the consent of all research subjects for human subjects in a life-threatening situation only if the IRB (including the concurrence of at least one licensed physician member of the IRB who is not otherwise involved in the project) finds and documents that all of the requirements of 21 CFR 50.24 are met. In emergency situations for which an exception from informed consent requirements is granted, the investigator shall be required to obtain informed consent from the subject or his/her authorized representative at the earliest feasible opportunity.

10.3 Assent (See also Section 19.4 regarding research with children and minors):

If a subject is not legally capable of giving informed consent or if the subject is cognitively impaired, the IRB must find that adequate provisions are made for soliciting the assent of the subject when in the judgment of the IRB, the subject is capable of providing assent. Failure to object to participation in a research study is not assent.

In determining whether subjects are capable of assenting, the IRB shall take into account the age, maturity, cognitive, and psychological state of the subject involved. This judgment may be required for each subject individually or for all subjects in a particular research study as the IRB deems appropriate. If the IRB determines that the capability of some or all of the subjects is so limited that they cannot reasonably be consulted or that the intervention or procedure involved in the research holds out a prospect of direct benefit that is important to the health or well-being of the subject and is available only in the context of the research, the assent of the subject is not a necessary condition for proceeding with the research.

10.4 Approval and Expiration Dates on Informed Consent Documents

Only the most-recently IRB approved Informed Consent may be used by the researcher to obtain consent for a study. Subject signatures on outdated informed consent documents will not be considered to reflect a valid consent process. Study personnel must be vigilant about ensuring that the most recently IRB-approved consent document is reviewed with a potential research participant. IRB-approved Informed Consents will have the TTUHSC seal and approval and expiration dates affixed to the document.

Approval Date
The date of approval of the informed consent document will be determined based on the type of
submission to the IRB. The approval date will be the date of final approval by the IRB for new studies, the date of continuing review approval for ongoing studies, or the date of approval of a modification to the informed consent document.

Expiration Date
The expiration date shall be the date of the expiration of the current IRB approval period. In the case of expedited reviews, the expiration date will be calculated based on the approval period recommended by the IRB Chair (or designee) using the date the initial IRB application or continuing review application was approved. In the case of full board reviews, the expiration date will be based upon the date that the IRB, at a convened meeting, voted to approve the study. If minor modifications are required prior to final approval (and stamping of an informed consent document) the actual approval period will be shortened based on the investigator's ability to make the requested changes in a timely and accurate manner.

10.5 Special Considerations for Tissue Bank Consent Documents

Tissue Bank Informed consent documents must contain language indicating whether or not the subject/donor will financially benefit from any product developed from their tissue. They must also have the current approval and expiration dates stamped on the consent documents. A sample consent template may be found in iRIS. See Section 21 for additional information regarding genetic research.
11.0 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

The HIPAA Authorization form or the Waiver of Authorization request form shall be included in initial applications for any project which utilizes protected health information. Once the HIPAA documentation has been reviewed for compliance with TTUHSC policy, it does not need to be re-submitted for the duration of the study, unless there are changes required on the HIPAA form.

Further information regarding HIPAA compliance, including approved forms, can be found at http://www.ttuhsc.edu/hipaa/

11.1 HIPAA Authorization

Each TTUHSC PI shall present subjects with an “Authorization to Use and/or Disclose Your Protected Health Information for Research Study” before using or disclosing protected health information (PHI). Such authorization shall satisfy the requirements of 45 CFR 164.508, except that the authorization may state that there is no expiration date or that the authorization continues in effect until the end of the research study. If there is any question as to whether PHI is being collected, contact your IRB administrator. Requests to alter HIPAA documents shall be submitted to the TTUHSC HIPAA Privacy Officer in the Office of Institutional Compliance (Lubbock).

Principal Investigators who are members of unaffiliated organizations that have designated TTUHSC as their Privacy Board may use the TTUHSC HIPAA authorization form that is found in iRIS. All references to TTUHSC should be deleted except as it pertains to the IRB stamp. This policy does not prohibit organizations from using their own HIPAA Authorization Form in addition to the TTUHSC HIPAA Authorization Form, should they so wish.

11.2 HIPAA Waiver Request to Privacy Board

Principal Investigators may request to use and disclose specified PHI without an individual’s specific authorization and/or without the necessity for an opportunity for the individual to agree or object for research purposes provided that the criteria required by 45 CFR 164.512(i) are satisfied. These criteria include:

- The intended use and/or disclosure of the Protected Health Information (PHI) involves no more than a minimal risk to the privacy of the individuals.
- The research could not practicably be conducted without the waiver.
- The research could not practicably be conducted without access to and use of the protected health information.

The form titled “Principal Investigator’s Request to Use and Disclose PHI without Authorization for Research Purposes” which can be found in iRIS is to be completed by investigators who wish to request a waiver of HIPAA Authorization. The same form is also used by investigators to request a review of PHI in preparation for research (to determine the number of patients seen with a particular diagnosis, for example) and for research using PHI of a decedent. The form should be submitted as part of the IRB application. It will be reviewed by a member of the Institutional Privacy Board and will be acknowledged as part of the IRB review process.

For purposes of HIPAA, the TTUHSC IRBs will act as Privacy Boards as defined by 45 C.F.R. Part 164.512(i). IRB Administrators shall verify Privacy Board Agreements with affiliated Entities are in place prior to a Privacy Board Review. The local IRB administrators/coordinators and the Director of RIO are members of the Privacy Board and may acknowledge HIPAA waiver requests.
12.0 RECRUITMENT AND ADVERTISING

12.1 IRB Approval of Recruitment/Advertising

Screening for Recruitment:
Investigators should check with their respective IRB Administrator or Privacy Officer prior to screening any subject population for possible inclusion in research. The researcher should check with the administrator, even if screening is used to determine if an adequate number of eligible subjects exists. HIPAA Waivers may be needed in this instance.

All Recruiting and Advertising Materials Must be Approved by the IRB:
When advertising is to be used, the IRB must review the information contained in the advertisement and the mode of its communication to determine that the procedure for recruiting participants is not coercive and does not state or imply a certainty of favorable outcome or other benefits beyond what is outlined in the consent document and the protocol. An expedited review may be used for approval, but advertising may be referred for full board review at the reviewer's discretion.

Any advertisement to recruit participants shall be limited to the information the prospective participants need to determine their eligibility and interest.

Advertising materials shall not include the following:

- claims, either explicit or implicit, that the drug, biologic, device or other type of intervention is safe or effective for the purposes under investigation;
- claims, either explicit or implicit, that the test article is known to be equivalent or superior to any other drug, biologic, device or intervention;
- terms such as "new treatment," "new medication" or "new drug" without explaining that the test article is investigational, meaning non FDA-approved;
- promise of "free medical treatment," when the intent is only to say that participants will not be charged for taking part in the investigation;
- an emphasis on the payment or the amount to be paid, by such means as larger or bold type. The IRB has the authority to approve whether compensation information shall be included in the advertisement.

Solicitations from the PI or any member of the research team to physicians, agencies, or others in order to recruit subjects must also be approved by the IRB prior to implementation.

Employees as Participants
No researcher may give an indication that an employee is required to participate as a research subject. No coercion or inference that employment status could be affected with respect to participation in research activities is allowed. TTUHSC employees who are paid for their participation in a research project should be informed that the compensation may be considered to be “additional compensation” from TTUHSC and will be taxed accordingly. Further information regarding payment of employees as research participants can be found in TTUHSC OP 72.19 (Participant Payment Policy).

Students as Participants
Students must always be informed if participation in research is a course requirement and they must be offered an alternative activity if they choose not to participate. The syllabus shall
clearly describe proposed participation in research activities for course credit and the alternative means of earning the course credit, which must require an equivalent amount of time and effort. The IRB shall review:

- that consent for participation is sought only under circumstances which minimize the possibility of coercion or undue influence,
- that methods used to maintain confidentiality are clearly identified, and
- that genuinely equivalent alternatives to participation are available.

Any IRB concerns regarding the use of students should promptly be forwarded to the Research Compliance Officer or to the EVPR.

12.2 Payments to Subjects

Payment to research subjects for participation in studies is not considered a benefit. Rather, it shall be considered compensation for time and inconvenience. The amount and schedule of all payments shall be presented to the IRB at the time of initial review. The IRB shall review both the amount of payment and the proposed method and timing of disbursement to determine that neither are coercive nor present undue influence.

Timing of Payments
Payment(s) shall be made to the subject in proportion to the portion of the study completed and shall not be contingent upon the subject completing the entire study. A schedule for the amount to be paid for each activity will not suffice; a timetable for the payments themselves must be submitted, approved, and presented to every subject as part of the Informed Consent process.

Method of Payments
The informed consent document must clearly establish how the subject is to be paid, i.e. cash, check, gift card, etc. Persons who receive more than $25 for participating in a research study must provide a social security number. Persons who are unable or unwilling to provide a social security number may be paid through TTUHSC’s DirectPay system, but the compensation will be subject to withholding. This information must be provided to the potential participant as part of the consent process. The description must also inform the subject if any money received will be reported to the Internal Revenue Service (receipt of $600 or more per year must be reported to the IRS). Additional details regarding acceptable methods of payment and income tax information can be found in TTUHSC OP 72.19.

Alterations in Payments
Any alterations in human research subject payment or revising of the payment schedule must be submitted to the IRB as an amendment prior to implementation. A document to be sent to the subjects informing them of payment changes must be part of this submission.

Documentation of Payments
The PI must keep documentation of payment(s) made to each subject in study files and for three years after the study is completed. All records shall be made accessible for inspection and copying by authorized TTUHSC representatives, including TTUHSC Accounting and Research Compliance personnel, TTUHSC auditors, the EVPR, and federal regulatory officials. Additional details can be found in HSC OP 72.19.

12.3 Finder’s Fees
Due to the conflict of interest created by offering such incentives, the TTUHSC IRBs will not allow the use of any form of compensation to individuals (including faculty, staff, students, family
members, etc.) who identify and/or recruit subjects for participation in a research study. Furthermore, physicians who recruit their own patients to serve as research subjects are ethically obligated to inform patients that they are in no way obligated to participate in the physician’s research projects.
13.0 PROPOSED CHANGES TO PREVIOUSLY APPROVED STUDIES

For previously approved projects (including exempt studies) all planned changes in the conduct of a study and/or changes to the consent document must be approved by the IRB prior to initiation of these changes.

Minor modifications proposed for previously approved studies may be reviewed (during the period for which approval was authorized) via expedited review in accordance with 45 CFR 46.110 and, when applicable, 21 CFR 56.110. A minor modification is defined as a change that would not materially affect an assessment of the risks and benefits of the study or does not substantially change the specific aims or design of the study. If the proposed change is eligible for expedited review, it will be sent to the IRB Chairperson or designee for review. The IRB Chairperson may not disapprove a requested modification via an expedited review procedure.

Examples of minor modifications that may receive expedited review include changes to advertisements, reduction in number of research participants, deletion of questions in a survey.

Some minor changes to a study can be acknowledged by the IRB office staff. These include personnel changes (other than changes to the principal investigator) correction of typos in study documents, or updated contact information.

Modifications of any study document (IRB Application, protocol, consent document, recruitment materials, etc.) require submission of an updated copy of the proposed revised document with changes clearly identified. All minor modifications which have been approved or acknowledged will be immediately available on the IRB agenda for review by all IRB members at any time.

Greater-than-minor modifications proposed for previously approved studies must be reviewed and approved (during the period for which approval was authorized) by the full board of the IRB during a convened meeting before the changes can be implemented. A major modification is defined as any change which materially affects the assessment of the risks and benefits of the study or substantially changes the specific aims or design of the study.

Examples of greater-than-minor changes include but are not limited to: newly discovered risks of the study drugs or study procedures, previously omitted or changed items that may affect the level of risk; an increase in the number of study subjects; a change in procedure that changes the level of risk for the study, or changes in the inclusion/exclusion criteria. Modifications of any study documents to the protocol require submission of an updated version of the relevant document.

The decisions and requirements for modifications by the IRB will be promptly conveyed to investigations in writing by the IRB Office. Written notification from the IRB Office of any decision to disapprove an amendment to a study will be accompanied by the reasons for the disapproval and an opportunity for the PI to reply, using iRIS. Replies are due within 30 calendar days of the date of written notice to the PI unless otherwise specified.
14.0 CONTINUING REVIEW OF APPROVED STUDIES

Continuing review of all research approved by the IRB, whether funded externally or not, will take place within a year of the initial review. This review must be substantive and meaningful. The IRB meeting minutes and the initial approval letter will indicate the review interval.

The frequency of the continuing review will primarily be based upon the degree of risk involved as determined by the IRB. Factors to be considered by the IRB in determining the appropriate interval for review may include, but are not limited to:

- involvement of vulnerable populations;
- location of research site;
- the involvement of recombinant DNA or other types of gene transfer studies;
- the use of waiver or alteration of informed consent procedures;
- classified research;
- research for which subjects would be exposed to additional risks, e.g. breach of confidentiality, Phase 1 studies, disproportionate number or severity of serious adverse events;
- previous suspension of the research due to compliance, record-keeping or other concerns;
- recommendations from other institutional committees;
- accrual information

In order to provide timely review and approval of each study, the PI shall submit required documentation no less than 10 days prior to the Full Board meeting preceding the study expiration date. Although reminders will be sent out, the PI is responsible for being aware of upcoming expiration dates in order to submit continuing review materials in a timely manner.

Information required for continuing review includes:

- Number of subjects enrolled, screened, and withdrawn (with reasons for withdrawal);
  Note that any participant who signs an informed consent document is considered to have been “enrolled” in the project, even if they are later withdrawn from the project (for not meeting all eligibility requirements, for example). Separate “screening” consent forms might be considered if an investigator anticipates a large number of “screen failures” for a particular project.
- A status report on the progress of the research and interim findings;
- Any information, including that from recent literature relevant to the study which might affect the possible benefits or risks/benefits to the subjects;
- A summary of any incidents of the following: adverse events, unanticipated problems involving the research, and/or complaints about the research since the last IRB review;
- Verification that informed consent was obtained from all subjects, that all subjects received a signed copy of the informed consent document and that all signed consent forms are on file (unless requirements were waived by the IRB);
- Summary of any previously unreported amendments or modifications to the research since the last review;
- An updated complete protocol (if changes have been made);
- Any relevant multi-center trial or Data Safety Monitoring Board (DSMB) reports, unless already submitted;
- Any other information which may be relevant to making a determination regarding the potential risks, benefits, or scientific merit of the study.
The primary reviewer will access the currently approved consent document in iRIS. Unless changes are being made to the consent document, investigators are not required to submit the currently approved consent document as part of the continuing review materials.

The approved continuing review template is found in iRIS. Based on its review, the IRB may require that the research be modified, restricted, suspended/terminated or administratively closed. Alternatively, previously imposed restrictions by the IRB may be lifted.

**Continuing review requiring full Board approval**
Studies that were originally approved by the Full Board and that are actively enrolling subjects or are continuing to provide study treatment to subjects require a Continuing Review by the Full Board. Documentation received prior to the submission deadline (see website for appropriate IRB) will be reviewed at the next regularly scheduled IRB meeting. The IRB review will include:

- An assessment of risks, benefits, and safeguards for human subjects;
- A determination that the currently approved or proposed informed consent document is accurate and complete; and
- A review of any significant new findings that may relate to the subjects’ willingness to continue participation.

**Continuing review NOT requiring full Board approval**
The following types of studies may receive expedited continuing review in accordance with applicable regulations:

- Studies that received expedited initial review;
- Studies in which enrollment has not yet taken place and no additional risks have been identified;
- Studies closed to accrual of new subjects and where subjects are no longer receiving study treatment. These studies must be reviewed at least annually until such time that there is no need to re-contact enrolled subjects.
- Studies in which only data analysis continues to take place.

The criteria for approval of a continuing review by expedited review procedures are the same as noted above for full board review.

**Failure to Provide Continuing Review Information.**
If a PI has failed to provide continuing review information to the IRB or the IRB has not reviewed and approved the research study by the continuing review date specified by the IRB, all research activity, including enrollment, data collection and analysis, shall stop unless the IRB finds that it is in the best interest of individual subjects to continue participating in the research interventions or interactions. Enrollment of new subjects cannot occur after the expiration of IRB approval.

**Submission of Continuing Review Materials after Expiration Date**
If IRB approval has expired, all research activity, including enrollment and accrual, data collection and analysis must stop effective the date of expiration. However, the IRB will permit the study to remain on the agenda pending continuing review if the PI submits the continuing review materials to the IRB within 30 calendar days after the expiration date. Exceptions to the 30-day deadline will be made by the IRB Chair on a case-by-case basis. Research activity shall resume only after IRB approval of continuing review. If the PI fails to
submit the continuing review materials within thirty days after the expiration date, the study will be closed administratively by the IRB. Studies that are administratively closed by the IRB are no longer approved for any research activity. An investigator who wishes to reinitiate a research protocol that has been cancelled must submit the project as an initial application.

**Exempt Studies**
Exempt studies are not approved by the IRB and do not require continuing review. However, on an annual basis investigators may receive a notice asking them to inform the IRB if there have been any changes in the study procedures that may remove the study from the Exempt category or affect the risk level of the study or whether the study is ongoing. There is no penalty for failure to reply.
15.0 PROTOCOL DEVIATIONS

Protocol deviations are unplanned or unforeseen changes in the implementation of an IRB-approved protocol. They generally refer to a modification of procedures that has already occurred for a single subject; they are not intended to modify the protocol. All protocol deviations are to be reported to the IRB along with a plan of correction to minimize the possibility of recurrence of the deviation. Minor protocol deviations will typically be acknowledged by a single reviewer, but will be available for review by all IRB members. Major protocol deviations will typically be deliberated by the full board at a convened meeting of the IRB.

15.1 Minor Protocol Deviations

Minor protocol deviations include:

- Deviations that do not increase the risk to the subjects;
- Deviations that do not affect the scientific validity of the study;
- Deviations that do not result from deliberate misconduct of the investigator;
- Deviations that do not necessitate any change to the approved protocol.

Examples of minor deviations include delayed follow-up visits (if no medication, treatment, or supervision is missed) short delays in the delivery of medication, or extra compensation inadvertently given to a study subject. Minor protocol deviations should be reported to the IRB promptly, generally within 30 days of the study team becoming aware of the deviation.

15.2 Major Protocol Deviations

These deviations must be reported to the IRB by the PI within 10 working days from when the PI becomes aware of them, and more quickly if serious harm results. Major protocol deviations include, but are not limited to:

- Deviations that increase the risk, including any deviation that results in a change in a subject’s medical status;
- Deviations that cause physical, mental, or psychological harm to a subject or otherwise impede a subject’s rights;
- Deviations that damage the scientific integrity of the study;
- Deviations as a result of deliberate misconduct on the part of the investigator;
- Deviations that cause the study to be seriously or continuously out of compliance with federal, state, or TTUHSC regulations;
- Failure to follow a corrective action plan.

Examples of major deviations include:
- Enrolling subjects who do not fulfill inclusion/exclusion criteria;
- Subjects receiving any research-related activity prior to approved informed consent being obtained;
- Observed inappropriate consent procedures
- Not reporting serious, unexpected adverse events;
- Variations in use of study device or in dispensing, dosing, or storing of research medications;
- Loss or corruption of study data;
- Incorrectly performing or missing tests or procedures required by the protocol;
• Premature “unblinding” of a subject;
• Anything identified by study personnel or a sponsor monitor that may affect the safety of a subject or integrity of data.

Questions about whether or not to report any particular occurrence may be directed to the respective IRB Administrator or Chair. However, study team members are urged to err on the side of caution if there is a question about whether or not to report a particular occurrence to the IRB. Protocol deviations will be reviewed as part of the research compliance audit process.
16.0 UNANTICIPATED PROBLEMS AND/OR ADVERSE EVENTS

The IRB is charged with the responsibility of reviewing reported unanticipated problems and adverse events involving risks to subjects in accordance with this policy. The IRB and/or EVPR has the authority to suspend/terminate approval of research that has been associated with unexpected serious harm to participants or others or for failure to conduct research in accordance with IRB approved protocol. In the case of a study’s suspension or a serious unforeseen risk, all appropriate reporting will take place. A more complete discussion of this section may be found in the OHRP Guidance found at http://www.hhs.gov/ohrp/policy/advevntguid.html

The PI and all study personnel are responsible for knowing the correct definitions for all terms used in this section. These definitions may be found in Appendix A – Glossary. Every time a defined term is used within this section, it will be italicized. If there is any question, RIO personnel and the appropriate IRB chair, in conjunction with the EVPR, will make the final determination as to the category of the event and any external reporting needs.

16.1 Unanticipated Problems (non-FDA regulated studies)

Unanticipated problems are events that are:

- Unexpected
- Related or possibly related to the study
- May pose a greater risk of harm than was previously expected.

Note that an unanticipated problem may or may not be an adverse event. Examples of unanticipated problems that are not adverse events are as follows. Each meets all 3 of the criteria for an unanticipated problem: (a) unexpected; (b) related to research participation; and (c) placed the subject or others at greater risk than previously identified.

- Stolen or lost sensitive, identifiable data.
- Gross pharmaceutical dosing error that resulted in no known harm to the subject.
- Donor sera were not appropriately screened.

Note that none of these examples represented any detectable harm or adverse effect to the subject, but each requires substantive changes in the protocol and/or informed consent or other corrective actions to protect the safety, welfare, and rights of the subject.

If an unanticipated problem is identified, it must be reported to the IRB within 7 days of the PI becoming aware of it. If the increased risk is significant, the IRB will notify the Institutional Official who will notify OHRP if necessary. The IRB will work with the PI in determining what other actions must be taken.

Any report of an unanticipated problem that is submitted to the IRB must contain the following information:

1. appropriate identifying information for the research proposal, such as the title, investigator’s name, and IRB number;
2. a detailed description of what happened;
3. an explanation of the basis for determining that the incident represents an unanticipated problem;
(4) a description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the unanticipated problem.

Unanticipated problems should be reported to the IRB using the “adverse event” report form in iRIS.

16.2 External Adverse Events

If an External Adverse Event is identified as:
- Unexpected;
- Serious
  AND
- having implications for the conduct of the study (e.g. requires a significant and usually safety-related change in the protocol)

it must be submitted to the IRB using the adverse event reporting form in iRIS. Typically, these events will result in changes to the study protocol, consent or other documents and will be reviewed as amendments by the IRB at a convened meeting. If the occurrence of External Adverse Event changes the risk status or any other element of the consent, an amendment must be filed with the IRB within 7 days of the investigator receiving the information, notifying the IRB of the event and the sponsor’s rationale for necessary changes. In some cases, the IRB or the study sponsor may choose to temporarily suspend enrollment in the research project until an updated protocol and consent form can be reviewed and approved by the IRB.

If an External Adverse Event does not meet all of the above criteria, it does not need to be submitted to the IRB. If a sponsor requires IRB submission, the PI may submit such events via iRIS and the submission will be acknowledged by the IRB Office. External adverse event reports that are submitted but do not meet all three criteria above will be acknowledged by the IRB office, and will be available for IRB members to review, but will generally not be individually deliberated at a convened meeting of the IRB.

16.3 Internal Adverse Events (FDA regulated studies)

PIs shall submit a written report to the IRB in writing--via the iRIS adverse event form-- all unanticipated (i.e. not consistent with the current investigator’s brochure or with other current risk information) adverse events or problems (both serious and non-serious):

- that involve research at TTUHSC or an affiliated entity
- that are known to be related or may possibly be related to the research activities
- within two (2) business days after the PI becomes aware of the event.
  - The PI is responsible for the accurate documentation, investigation and follow-up of all possible study-related adverse events and other unanticipated problems.
  - Reports of all unanticipated adverse events must be retained in both the PI files and the IRB office files for reference if needed.

The IRB may conduct an expedited review of the event if there is no change in the risk/benefit ratio, the research proposal, or the consent form; otherwise, full Board review at a convened meeting of the IRB is required. The Chair or designee, at the time of expedited review, may refer any adverse event to the full Board for review.
16.4 Serious Adverse Events (SAEs)

By definition, Serious Adverse Events (SAEs) are internal events. All PIs shall submit a written report to the IRB via iRIS:

Serious adverse events include:

(i) Death
(ii) Life-threatening experience
(iii) Hospitalization (for a person not already hospitalized)
(iv) Prolongation of hospitalization (for a person already hospitalized)
(v) Persistent of significant disability or incapacity
(vi) Congenital anomaly and/or birth defects
(vii) Any event that jeopardizes the subject and may require medical or surgical treatment to prevent one of the preceding outcomes.

These events should be reported to the IRB as soon as possible, but in any event, no later than two (2) business days after the PI becomes aware of the event. The event should be reported via the “internal adverse event” report form in iRIS.

For non-FDA regulated research projects that will have expected SAE’s (research with pregnant women where hospitalization for childbirth is expected during the time of the research, for example) investigators may request permission from the IRB at the time of the initial review or via an amendment to not report all SAEs as they occur. These requests will be reviewed on an individual basis by the IRB.

When an SAE is reported to the IRB, The EVPR, in conjunction with RIO personnel, and the appropriate IRB chair will make the final determination of the category of the event and any external reporting needs.
17.0 STUDY CLOSURE/TERMINATION/SUSPENSION

17.1 Study Closures

Studies which have been approved by the IRB may be closed by the investigator, the sponsor, the IRB, TTUHSC, or by an affiliated entity. When the decision to permanently or temporarly close a study is made by the investigator, an affiliated entity, or the study sponsor, the PI must promptly notify the IRB through iRIS and include a summary of findings to date.

Completed Studies
Studies that have been completed, including final data analysis, and are closed at the local research site, will be designated as “Completed” in iRIS. The PI shall submit the “Study Closure Report” to the IRB, which will include the total number of subjects, any major problems, and a summary of the findings. A manuscript may be substituted for the summary of the findings. Once a study is designated “Completed”, any links (codes, etc.) between the data and identifiers must be destroyed and well as any videos, tapes, etc. that were targeted for destruction at the completion of the study. Study materials must be stored for a minimum of 3 years, and must be stored as long as additional applicable federal or contractual regulations stipulate.

Once the IRB has sent a written acknowledgment that the study is designated “Completed”, no further actions are necessary by the PI.

Cancelled Studies
If, after IRB approval, a study is permanently closed by the researcher or sponsor for any reason prior to its completion, it will be designated as “Cancelled” in iRIS. The PI shall submit the “Study Closure Report” to the IRB, which will include the total number of subjects approved and enrolled, any major problems, and a summary of the findings. Once a study is designated "Cancelled", any links (codes, etc.) between the data and identifiers must be destroyed and well as any videos, tapes, etc. that were targeted for destruction at the completion of the study. Once the IRB has sent a written acknowledgment that the study is designated “Cancelled”, no further actions are necessary by the PI.

Temporarily Closed Studies
Studies that are temporarily closed to accrual of new subjects by the PI, Sponsor, or IRB will be placed in “Closed to Accrual” status in iRIS. No new subject enrollment may take place while studies have this designation. Continuing reviews of the research by the IRB are required when a study is in this status. Unless otherwise determined and communicated in writing to the investigator by the sponsor or IRB, subjects who had previously consented to participate in the research project may continue to complete protocol requirements while the study is closed to enrollment of new subjects.

The IRB will send written acknowledgement of the temporary closure status, and it is lifted only by written notice from the IRB. If the sponsor has temporarily closed the study, the PI must notify the IRB upon its closure and when the sponsor re-opens it. Screening and/or enrollment of new subjects may not resume until the PI receives written approval from the IRB.

Administratively Closed Studies
Studies may be "Administratively Closed" by written notice to the PI by the IRB for reasons including, but not limited to:

• non-responsiveness to requests for information from the investigator, or
• no enrollment of subjects in the study for a period of three or more years.
No further research activity is permitted for studies which are administratively closed. Any further activity on such studies will require the submission of a new application to the IRB.

17.2 Suspension/Termination of Approval for Cause

The IRB and/or the EVPR have authority to suspend/terminate research for cause. The term “Suspension/Termination” applies when the IRB withdraws its approval from a study for any of the following causes (45 CFR 46 and 21 CFR 56):

- unanticipated problems involving risks to subjects or others;
- serious or continuing noncompliance with regulations governing human subjects research;
- research not being conducted in accordance with the requirements or determinations of the IRB.

Notification of suspension/termination requires immediate cessation of all research activities, including research visits for subjects enrolled in the study, unless the Principal Investigator provides information in writing to the IRB indicating that failure to perform study-related procedures on previously enrolled subjects would be detrimental to the subjects’ health or welfare. Any data analyses must also halt at the time of suspension or termination of IRB approval. Suspension or termination of IRB approval will always result in reporting of the suspension/termination to federal regulatory agencies by TTUHSC.

The PI shall be immediately notified in writing of suspension/termination of IRB approval along with the reasons for the suspension/termination. The EVPR shall promptly report suspension/termination of research to the appropriate federal agencies in compliance with federal regulations and TTUHSC policy.

Studies that have been terminated/suspended require submission of a written Correction Plan by the PI and approval by the IRB before any research can resume. Suspended studies shall require ongoing continuing review by the IRB.

17.3 Appeal of Suspension/Termination

The PI may appeal the decision of the IRB or EVPR by submitting a written request to the IRB or EVPR, as applicable, and provide a rationale for the appeal and any other supporting documentation. The PI must submit an appeal within five business days of the date of notification of suspension/termination.

Review by Subcommittee and Recommendation to Board

Within 14 days of the appeal of suspension, the PI’s request for reconsideration shall be reviewed by a subcommittee consisting of the IRB Chair and two IRB members jointly selected by the IRB Chair and Senior Director of RIO. The subcommittee may also invite individuals with expertise in that area of research to assist the subcommittee in its review of the issues. The local IRB Administrator, Research Compliance Officer, and Senior Director of the RIO will provide assistance to the subcommittee as needed, though they will not be considered members of the subcommittee. Individuals assisting the subcommittee shall maintain confidentiality of the IRB proceedings.

This subcommittee shall review the PI’s documentation, the research, the suspension
documentation, and may speak with the PI. The subcommittee shall submit findings and recommendation to the full Board at its next regularly scheduled meeting, if possible. At the discretion and invitation of the subcommittee, the PI may address the IRB in person at its next regularly scheduled meeting.

Decision by Board

The Full Board shall consider the subcommittee’s recommendation(s) and make a ruling to accept, reject, or revise the Subcommittee’s recommendation(s).

If the subcommittee recommends that suspension be upheld and the IRB accepts this recommendation, this decision falls under disapproval of research involving human subjects, and there is no further appeal within TTUHSC. (45 CFR 46.112 and 21 CFR56.112).

A decision by the full IRB to disapprove, suspend/terminate a research project is final and may not be reversed by the EVPR or any other officer/agency of TTUHSC or affiliated entities.

Faculty Grievance Policies Not Applicable

TTUHSC Schools have faculty grievance policies to address grievances of faculty members through and with their supervisors. A school faculty grievance procedure is not available to appeal an IRB decision with respect to research.
18.0 INVESTIGATIONAL DRUGS/DEVICES

IND/IDE Application

The use of an unapproved investigational drug, device or biologic requires an FDA investigational new drug application (IND) as detailed in 21 CFR 312 or a FDA investigational device exemption (IDE), detailed in 21 CFR 812.

18.1 IND Application

Before submitting an application to the IRB that involves an investigational new drug or biologic, the PI must secure an IND number and approval from the FDA or correspondence from the FDA waiving this requirement. This FDA number or letter waiving the requirement for an FDA number shall be included in the submission to the IRB.

18.2 Special Requirements for an IDE Application

The IDE regulations specify that there are two different types of device studies, “significant” risk (SR) and “nonsignificant” risk: (NSR). The determination is initially made by the device manufacturer and must be made based on the proposed use of a device in and investigation, not just on the device alone. The IRB must review the risk level.

SR Studies
- An SR device study is defined as a study of a device that presents a potential for serious risk to the health, safety, or welfare of a subject and (1) is intended as an implant; or (2) is used in supporting or sustaining human life; or (3) is of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health; or (4) otherwise presents the potential for serious risk to the health, safety, or welfare of a subject.
- Determination of SR is made by sponsor.
- Must be reviewed by the IRB.
- Governed By Investigational Device Exemption (IDE) regulations (21CFR 812)
- Both IRB and FDA must approve the investigation
- IRB should consider information including results of prior investigations using device; proposed investigational plan; subject selection criteria; and monitoring procedures
- Sponsor must furnish the IRB with a risk assessment and the rationale for making the determination [21 CFR 812.150(b)(10)].

NSR Studies
- An NSR study investigation is one that does not meet the definition of a serious risk study. Both SR and NSR studies require initial and continuing IRB approval and informed consent.
- Determination of NSR is made by the sponsor.
- IRB acts as FDA surrogate because sponsors are not required to report NSR device study approvals to the FDA.

IRB Risk Determination
The IRB may agree or disagree with sponsor’s NSR designation.
- If IRB agrees and approves study, it may begin without submission of an IDE application to the FDA.
- If IRB disagrees, the IRB will notify the sponsor who must notify the FDA that an SR
determination has been made and apply for approval of an IDE application.

The IRB minutes must document the rationale for SR/NSR and subsequent approval or disapproval decisions for clinical investigations.

18.3 Emergency Use of Investigational Drug/Device

Emergency use is defined as the use of an investigational drug or biological product or investigational medical device with a human subject in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval [21 CFR 56.102(d)]. This is sometimes referred to as "compassionate use."

The emergency use provision in the FDA regulations [21 CFR 56.104(c)] is an exemption from prior review and approval by the IRB. The exemption, which may not be used unless all of the conditions described in 21 CFR 56.102(d) exist, allows for one emergency use of a test article without prospective IRB review. FDA regulations require that any subsequent use of the investigational product at the institution have prospective IRB review and approval. The FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.

Life-threatening, for the purposes of section 56.102(d), includes the scope of both life-threatening and severely debilitating, as defined below.

- Life-threatening means diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival. The criteria for life-threatening do not require the condition to be immediately life-threatening or to immediately result in death. Rather, the patient must be in a life-threatening situation requiring intervention before review at a convened meeting of the IRB is feasible.
- Severely debilitating means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.

When possible, physicians will be asked to notify the IRB when a situation arises that calls for the emergency use of a test article. The notification should include the following information:

- physician's name, contact information and affiliation with TTUHSC
- the patient's initials and diagnosis
- name of the test article to be used
- date the test article was (will be) administered
- a complete description of the patient's condition and an explanation of why the emergency use of the test article is (was) required; that is, the patient is (was) in a life-threatening situation; there is (was) no standard acceptable treatment available; there is (was) not sufficient time to obtain IRB approval.

This notification will be reviewed by the IRB Chairperson or designee and a written response will be provided to the physician. The response should not be construed as an IRB approval but instead will be used by the IRB to initiate tracking to ensure that the physician files a report.
within the 5-day time-frame required by 21 CFR 56.104(c). This report should include the following:

- Physician's name
- Patient's Name and Diagnosis
- Name of Drug/Biologic/Device
- Date the test article was administered/utilized
- brief description of the results of the emergency use, including patient outcome, if known, any adverse events or unanticipated problems

In addition, the physician should evaluate the likelihood of needing to use the test article again and, if additional use is anticipated, immediately submit a protocol and consent for full IRB review.

Templates for the notification and response letters can be obtained from the local IRB office.

Some manufacturers will agree to allow the use of the test article, but their policy requires "an IRB approval letter" before the test article will be shipped. If it is not possible to convene a quorum of the IRB within the time available, some IRBs have sent to the sponsor a written statement that the IRB is aware of the proposed use and considers the use to meet the requirements of 21 CFR 56.104(c). Although, this is not an "IRB approval," the acknowledgment letter has been acceptable to manufacturers and has allowed the shipment to proceed.

18.4 Unanticipated Adverse Device Effects

This is a category of adverse events. When there is an unexpected adverse event involving a device, there are different reporting requirements. In this case, sponsors must report the unexpected adverse event directly to the IRB, not to the investigator. This report must be made within 10 days of the sponsor’s receipt of the information. The full board of the IRB must then determine if the level of risk has changed. The PI will be notified in iRIS of the IRB’s decision.
19.0 SPECIAL CATEGORIES OF RESEARCH

On a case-by-case basis, and with appropriate confidentiality safeguards, the IRB may request review by an individual with competence in an area not represented by the Board membership. If research with children and minors and/or pregnant women and fetuses is being reviewed, strong consideration should be given to using consultants if qualified members are not on the IRB board.

19.1 Pregnant women and fetuses

Special DHHS regulations applying to pregnant women and fetuses may be found in 45 CFR 46 Subpart B. No research may be conducted with pregnant women or fetuses unless the conditions specified in 45 CFR 46 Subpart B are met.

When the IRB considers research with pregnant women, the following conditions must be met.

- If scientifically appropriate, preclinical studies, animal studies and studies on non-pregnant women should have already been completed.
- Any risk to the fetus must be caused only by procedures that hold out the prospect of direct benefit for the woman or the fetus. If there is no prospect of benefit, the risk to the fetus must be minimal and the purpose of the research is the development of important biomedical knowledge that cannot be obtained by any other means.
- There must be the least possible risk possible to achieve the objective.
- If there is potential benefit to the mother, potential benefit to the mother and fetus, or no potential benefit to either the mother or fetus AND the risk to the fetus is minimal AND the research can lead to important biomedical knowledge that cannot be obtained by other means, then the mother alone may provide consent for the study.
- If the research holds out the prospect of direct benefit only to the fetus, then the consent of BOTH the mother and father is necessary unless the father is unavailable, incompetent, temporarily incapacitated, or the pregnancy is the result of rape or incest.
- Each person giving consent is fully aware of the impact of the research on the fetus or neonate.
- If the pregnant woman is a child, assent and permission must be obtained in accordance with 45 CFR 46 Subpart D.
- No inducement may be offered to terminate a pregnancy.
- Individuals involved in the research may have no involvement in any decisions regarding the termination of the pregnancy or the viability of a neonate.

19.2 Research Involving Neonates

Regardless of neonate viability, all research involving neonates must meet the following conditions:

- Where scientifically appropriate, preclinical and clinical studies have been conducted and provide data for assessing potential risks to neonates.
- Each individual providing consent is informed regarding the reasonably foreseeable impact of the research on the neonate.
- Individuals involved in the research will have no part in determining the viability of the neonate.

Neonates of Uncertain Viability
No research may take place until the following conditions have been met:

(1) The IRB finds that:

• The research holds out the prospect of enhancing the probability of survival of the neonate to the point of viability, and any risk is the least possible for achieving that objective; or
• The purpose of the research is the development of important biomedical knowledge which cannot be obtained by other means and there will be no added risk to the neonate resulting from the research; and

(2) The legally effective informed consent of either parent of the neonate or, if neither parent is able to consent because of unavailability, incompetence, or temporary incapacity, the legally effective informed consent of either parent’s designated representative is obtained as stated in the section above. The consent of the father or his representative does not need to be obtained if the pregnancy resulted from rape or incest.

Nonviable Neonates
After delivery, nonviable neonates may not be involved in research covered by this policy unless all of the following conditions are met:

• Vital functions are not artificially maintained;
• The research will not terminate the heartbeat or respiration of the neonate.
• There will be no added risk to the neonate resulting from the research;
• The purpose of the research is the development of important biomedical knowledge that cannot be obtained by other means; and
• The legally effective informed consent of both parents of the neonate is obtained, except under the circumstances listed above; a representative’s signature is not allowed. The consent does not have to specify risks to the neonate.

Viable Neonates
Research may be done after delivery of a viable neonate if all rules following informed consent (Section 10) and research with children (Section 19.3) are followed.

Research Involving the Placenta, the Dead Fetus or Fetal material.
Research involving, after delivery, the placenta; the dead fetus; macerated fetal material; or cells, tissue, or organs excised from a dead fetus, shall be conducted only in accord with any applicable federal, state, or local laws and regulations regarding such activities.

If information associated with material described in previous paragraph of this section is recorded for research purposes in a manner that living individuals can be identified, directly or through identifiers linked to those individuals, those individuals are research subjects and all pertinent subparts of this part are applicable.

Research Not Otherwise Approvable Which Presents an Opportunity to Understand, Prevent, or Alleviate a Serious Problem Affecting the Health or Welfare of Pregnant Women, Fetuses, or Neonates.
This type of research can be conducted (or receive federal funding) only if:

• The IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses or neonates; and
• The Secretary of DHHS, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, ethics, law) and following opportunity for public review and comment, including a public meeting announced in the FEDERAL REGISTER, has determined either:

(1) That the research in fact satisfies the conditions of regulations, as applicable; or

(2) The following:
   (i) The research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of pregnant women, fetuses or neonates;
   (ii) The research will be conducted in accord with sound ethical principles; and
   (iii) Informed consent will be obtained in accord with the informed consent provisions.

19.3 Prisoners

Special DHHS regulations applying to prisoners may be found in 45 CFR 46, Subpart C. No research may be conducted with prisoners unless the conditions set forth in 45 CFR 46.305 and 46.306 have been met and are reflected in the IRB minutes. (See also Section 2.8). Research involving prisoners may not be exempted nor may initial reviews involving prisoners be expedited; there must be full board review.

Definition of Prisoners
Prisoners are any individuals involuntarily confined or detained in a penal institution. It includes persons who are detained pending arraignment, trial, or sentencing, and persons who become prisoners after research has begun.

Types of Research Permitted

The following categories are listed in 45 CFR 46, Subpart C [section 306(a)(2)].

1. Study of the possible causes, effects, and processes of incarceration, and of criminal behavior; or
2. Study of prisons as institutional structures or of prisoners as incarcerated persons.

Because categories 1 and 2 likely do not directly benefit the subject, studies in these categories can carry no more than minimal risk.

3. Research on conditions particularly affecting prisoners as a class (e.g. vaccines on illnesses that are more prevalent in prisons than elsewhere; research on psychological/social problems); or
4. Research on practices, accepted or innovative, that may have the intent and expectation of improving the health or well-being of the subject and require control groups who will not benefit from the research.

For categories 3 and 4, the IRB administrator/coordinator will write the requisite letter to the Secretary of DHHS or a designee and follow the Informal Subpart C Document; Prisoner Research Certification Letters to OHRP, updated August 3, 2003, or a later version if such is issued.
Approval Criteria for Prisoner Research

Before research with prisoners can be approved by the IRB, subpart C specifies that the following additional requirements must be met. Each specific requirement must be addressed by the IRB with discussion, if any, reflected under the specific condition in the IRB minutes. Each condition must be voted on separately, and each vote must be recorded under the appropriate condition in the IRB minutes.

- The research being reviewed falls into either category 1, 2, 3, or 4 listed above.
- Any possible advantages to prisoners participating in the proposed research do not outweigh the risks associated with the research. Discussion of this point should take into account the limited choices available in a prison environment.
- The risks to the prisoners are no greater than they would be to non-prisoners involved in the same research.
- All prisoners who meet study eligibility criteria must be considered for participation without arbitrary intervention by authorities or other prisoners. Unless the IRB members are provided written justification for other procedures, all subjects in control groups must be chosen randomly from the pool of eligible subjects.
- Information about the study must be presented to the subjects clearly and in a form that is understandable.
- Adequate assurance is given to the prisoner that participation or lack of participation in the study will not affect chances of parole. Additionally, there must be adequate assurance that parole boards will not consider the individuals participation or lack of participation in the study when making a decision.
- The IRB members must consider if there may be a need for follow-up care of participants after their part in the study has concluded and whether provision for this follow-up has been made, taking into account the varying length of the participant’s sentences and whether the participant has been informed of this fact.

Prisoner Advocate
Federal Regulations require that the IRB membership be modified if it is to review research involving prisoners. Therefore, if any IRB will review research involving prisoners, at least one member of the IRB shall be a prisoner, or a prisoner advocate with appropriate background and experience to serve in that capacity. Research within the TTUHSC system may be reviewed by any IRB with a prisoner advocate.

19.4 Children and Minors

In Texas, the age of majority is 18. The information in this section applies to minors under the age of 18 who are not considered legally emancipated.

The TTUHSC IRBs will follow 45 CFR 46 subpart D, which provides special safeguards for children and minors when they are subjects in research studies. In addition, the TTUHSC IRBs adopt all Food and Drug Administration regulations found in 21 CFR 56 subpart D.

When children or minors are research subjects, researchers must obtain both the consent of the parent or representative and the assent of the child if he/she is 7 years or older. Mere failure to object is not assent. In certain cases, the IRB can waive or modify the assent requirement. Investigators wishing to waive or modify the assent requirement should submit their request to the IRB either as part of the initial application or in an amendment for previously approved
studies.

**Additional Required Determinations**
The IRB can approve research involving children only if it falls into one of the following categories. The chosen category (45 CFR 46.404-407; 21 CFR 50.51-54) will be documented in the IRB meeting minutes.

1. Research presenting no greater than minimal risk to children.
2. Research involving greater than minimal risk of children that offers the prospect of direct benefit or may contribute to the well-being of the individual child.
3. Research involving only a minor increase over minimal risk, yet does not offer any, prospect of direct benefit or contribute to the well-being of the child.

Federally funded research that does not fit into one of these categories must either be disapproved or referred to the Secretary of the Department of Health and Human Services (DHHS). Minimal risk is defined as follows: the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical and or psychological examinations or tests. This standard is indexed to the lives of healthy children.

**Child or Minor Representative on IRB**
An IRB considering a study involving children as subjects shall:

1. assess its needs for pediatric medical experience among the IRB voting membership to assure that it possesses the professional competence necessary to review the specific research activities and
2. consider inclusion of one or more individuals who are knowledgeable about and have professional medical experience with children. To fulfill this requirement, the IRB may invite non-voting individuals to assist in the review of issues which require expertise beyond, or in addition to, that available among voting IRB members.

**Assent of Child or Minor**
Assent is a child's/minor's affirmative agreement to participate in research. If a child/minor merely does not refuse to participate in research, assent has not been obtained. While the IRB may use its discretion as to whether assent of a child/minor is required, and how this shall be obtained (i.e., orally, in writing, etc.), in general, children age 7 and over should be allowed the opportunity to assent. Opportunities for assent should be made in language and under circumstances that insure that the child/minor understands and minimizes or alleviates a feeling of pressure to participate by parents or professionals. Assent may be waived under normal circumstances where consent would be waived, or if the research offers a promise of direct benefit not available outside of the research and the parent consents.

Parents or guardians of the child/minor must give consent for the child/minor to participate in research unless the IRB determines that, for the protection of the child/minor (e.g. research on neglected or abused children), consent of the parent/guardian is not required. In such a case, the IRB must go to extraordinary lengths to insure that the rights of the child/minor are protected.

**Placebo Controls**
Placebo groups are not specifically prohibited in children’s research, but they may be used only in studies where there is no proven prophylactic, diagnostic, or therapeutic treatment in
existence. The IRB must consider the risks and benefits to the child of the study without concern for the success or failure of the study.

Wards

Children who are wards of the State or any other agency, institution, or entity can be included in research approved under applicable federal regulations only if such research is:

- related to their status as wards; or
- conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards.

If the research is approved, the IRB shall require appointment of an advocate for each child who is a ward, in addition to any other individual acting on behalf of the child as guardian or in loco parentis. One individual may serve as advocate for more than one child. The advocate shall be an individual who has the background and experience to act in, and agrees to act in, the best interests of the child for the duration of the child's participation in the research and who is not associated in any way (except in the role as advocate or member of the IRB) with the research, the investigator(s), or the guardian organization.
20.0 DATA SAFETY MONITORING BOARD (DSMB)/DATA MONITORING COMMITTEE (DMC) REPORTS

Data Safety Monitoring Boards (DSMB)/Data Monitoring Committees (DMC) are boards established by commercial or governmental sponsors of multi-site research. These boards review the adverse event reports from all participating sites and make reports on the safety of the project to all participating institutions.

Investigators shall submit any independent DSMB/DMC reports to the IRB within five (5) business days from the date the information is received by the PI. The IRB Administrator may simply acknowledge receipt of these documents if there are no changes in the conduct of the study. If problems are indicated, the administrator will promptly forward the report to the IRB chair/designee for appropriate action.

Any documents resulting from DSMB/DMC reports, e.g. amendments, revised consents, must be submitted prior to the next meeting of the IRB.
21.0 GENETIC RESEARCH

Genetic information must be carefully maintained in order to protect against stigmatization, discrimination, or significant psychological harm to the subject. In general, genetic research is defined as an analysis of human DNA, RNA, chromosomes, proteins, or metabolites that detect genotypes, mutations, or chromosomal changes. Routine tests that do not detect genotypes, mutations, or chromosomal changes, such as complete blood counts, cholesterol tests, and liver enzyme tests, are not typically considered genetic tests. Also, genetic tests do not include analyses of proteins or metabolites that are directly related to a manifested disease, disorder, or pathological condition that could reasonably be detected by a health care professional with appropriate training and expertise in the field of medicine involved.

When reviewing genetic research, the IRB will consider the following issues in both the application and the informed consent document, as applicable:

- Information that can be obtained from DNA samples in general, and the specific questions to be addressed in this study.
- The extent of subject and sample confidentiality if the sample and subsequent information will be part of a registry or database (see information on GINA, below).
- The rights and limitations of subjects to request destruction or removal of their sample and/or associated data at a future date. The rights and limitations of subjects to request that their sample and or associated data be stripped of any identifying information.
- Identifying information available to other researchers if their sample and/or associated data are part of a registry or database.
- Mechanisms for maintaining confidentiality in long-term studies, registries, or databases.
- Potential for commercial profit by the entity, PI or sponsor from information gathered in this study.
- A clear statement of financial benefit to subject in tissue bank consent documents using IRB approved financial benefit language.
- The availability or access to genetic counseling in cases where a study may reveal genetically important information (i.e., possessing genetic defects which could be passed on).
- A clear statement that the sample/data, any cell lines, profits from data etc., are the property of TTUHSC or the entity sponsoring the research.
- If genetic information will be disclosed to the subject or another party, the PI disclosing the information must be named and the specific genetic information being disclosed must be stated.
- Information disclosed must be in a manner consistent with the recipient's level of knowledge, e.g., information would be phrased differently when disclosed to a lay person versus a physician.
- Subjects must have the right to decline receiving genetic information.
- In the absence of a specific authorization to maintain a DNA sample, DNA samples collected and stored or analyzed in connection with a research project shall be destroyed upon completion of the project or withdrawal of the individual from the project. This information must be clearly stated in the informed consent document.

Minors
For genetic research involving minors, the informed consent document must give parents/guardians the option of whether or not they want the results (if available) of the genetic
analysis disclosed to them. Whenever appropriate, the minor’s assent shall be solicited. When minors reach maturity, they shall be re-consented if identifiers are taken.

**Genetic Relationships**
In some cases it may be possible to determine that some members of the family are not genetic relatives. Issues of genetic relationships (paternity or maternity, as could be hidden by adoption or donor fertilization) and other incidental information shall not be revealed to the subject.

**21.1 Genetic Information Nondiscrimination Act (GINA)**
The following information should be included in TTUHSC informed consent documents when genetic testing is part of the research protocol.

A new Federal law, called the Genetic Information Nondiscrimination Act (GINA) generally makes it illegal for health insurance companies, group health plans and most employers to discriminate against a research subject based on genetic information. This law generally will protect research subjects by prohibiting health insurance companies and group health insurance plans from requesting genetic information that is collected in a research study. Health insurance companies and group health plans are also prohibited from using genetic information when making decisions regarding eligibility or premiums. Employers with 15 or more employees may not use genetic information obtained from research when making a decision to hire, promote or fire an employee or in setting conditions of employment.

All health insurance companies and group health plans must follow this law by May 21, 2010. All employers with 15 or more employees must follow this law as of November 21, 2009.

This Federal law does not protect against genetic discrimination by companies that sell life, disability, or long-term care insurance.

More information about the impact of GINA on research can be found in the following OHRP Guidance document: [http://www.hhs.gov/ohrp/policy/gina.pdf](http://www.hhs.gov/ohrp/policy/gina.pdf)
22.0 HUMAN BIOLOGICAL SPECIMENS

All prospective collection of human specimens for research requires prior written IRB approval and informed consent from the subject (unless consent is waived by the IRB – see Section 10.2).

The secondary use of existing human specimens for research purposes can be permitted under certain circumstances. Some types of secondary use require IRB review and may require informed consent from subjects.

22.1 Prospective Collection and Use of Human Specimens for Research Purposes

IRB approval is required for the prospective collection and research use of human specimens obtained explicitly for research purposes. Examples include extra blood taken for a research project at the time of a clinical blood draw, or additional biopsies performed for research purposes during a clinically indicated procedure. IRB review and approval is required even if the work is being done off campus, for example, if an investigator travels to a remote site to collect the specimens. The IRB will typically require written consent/authorization of each research participant.

22.2. Use of EXISTING Human Specimens for Research Purposes

De-identified commercially-available human cells or cell lines
IRB review is not required for laboratory research on human cells obtained from commercial or governmental entities because the release of these samples to investigators does not meet the regulatory definition of human subjects research. When human cells are obtained from one of these repositories, investigators are reminded to review the contract or purchase agreement carefully to ensure that the planned use of the specimens will be in accordance with the vendor’s or supplier’s terms and conditions. Exception: permission is required for use of human embryonic stem cells, regardless of source.

Fee-for-service analyses of human cells or cell lines
TTUHSC IRB review is not required for activities limited to the performance of analyses on human specimens as a commercial or genuinely non-collaborative service. For example, appropriately qualified laboratory staff may perform analyses of blood samples for investigators outside of TTUHSC solely on a commercial (non-collaborative) basis.

Identifiable commercially available human cells or cell lines
IRB review and approval is required for laboratory research on identifiable human specimens obtained from commercial or governmental entities. Depending on the nature of the research, these types of projects may be classified as exempt from formal IRB review (See Section 6.0) but the IRB, not the investigator, will make this determination.

Identifiable human cells or cell lines obtained from collaborators outside of TTUHSC
IRB review is required for research involving identifiable human specimens obtained from collaborators outside of TTUHSC. Depending on the nature of the research, these types of projects may be classified as exempt from formal IRB review (See Section 6.0) but the IRB, not the investigator, will make this determination.

Secondary use of identifiable previously-collected excess (i.e., otherwise discardable) clinical specimens from within TTUHSC or its affiliates
IRB review is required for any proposed research use of excess clinical specimens obtained from Pathology or from related services within TTUHSC and its affiliates. Examples include specimens collected for diagnostic purposes or during surgery in the clinical laboratories (including pathology) or in clinical care areas, such as the operating suites.

22.3 Special Categories of biological specimens

Human embryonic stem cells (hESC)
TTUHSC permission is required for research on existing hESC lines and IRB approval is required for the derivation of new hESC lines. In addition, there are other special ethical, legal, financial, and institutional issues related to the research use of hESC. Investigators are asked to contact the IRB prior to any use of hESC cells or any derivation of new hESC lines at TTUHSC or its affiliated hospitals.

Fetal Tissue Specimens
IRB review is required for research on fetal tissue. Note: federal law prohibits the sale of fetal tissue for profit.

Transfer of samples to research collaborators outside of TTUHSC
The IRB must review any plan to transfer human specimens that were collected for research purposes (generally as part of a TTUHSC IRB-approve tissue repository) to outside collaborators for research. In addition, a Materials Transfer Agreement (MTA) may be required with the recipient entity. For more information, please contact the TTUHSC Office of Sponsored Programs. Note: The transfer of non-identifiable human specimens from an IRB-approved TTUHSC Tissue Repository to another investigator, if approved by the IRB as one of the procedures of the tissue bank, does NOT require separate IRB review and approval. This is because the IRB already will have reviewed and approved the procedures of the Tissue Repository, which describe such transfers.
23.0 CERTIFICATE OF CONFIDENTIALITY

Data collection about sensitive issues (such as illegal behavior, alcohol or drug use, or sexual practices or preferences) requires the protection of confidentiality beyond preventing accidental disclosures. Under federal law, an advance grant of confidentiality, known as a Certificate of Confidentiality is available. General information may be found at http://grants.nih.gov/grants/policy/coc/.

A Certificate of Confidentiality provides protection for the researcher and the subjects against compelled disclosure of identifying information about subjects of biomedical, behavioral, clinical, and other research (Public Health Service Act 301(d), 42 U.S.C. 241(d)). Under this Act, the Secretary of HHS may authorize persons engaged in research to protect the privacy of subjects by withholding the names or other identifying characteristics of the subjects from all persons not connected with the conduct of the research. This means that researchers may not be compelled in any Federal, State or local civil, criminal, administrative, legislative, or other proceedings to identify their subjects.

The Confidentiality Certificate does not govern the voluntary disclosure of identifying characteristics of research subjects but only protects subjects from compelled disclosure of identifying characteristics by the researcher. Researchers, therefore, are not prevented from the voluntary disclosure of matters such as child abuse or a subject's threatened violence to self or others. If an investigator intends to make such voluntary disclosures, however, the consent form shall clearly indicate this possibility to subjects.

In order to seek a Certificate of Confidentiality, a PI shall identify the potential for compelled disclosure in the application. The consent document shall also include and describe possible disclosure situations. The IRB shall determine whether the risks to subjects are minimized, informed consent is appropriate, and privacy and confidentiality protections are adequate. Detailed instructions for obtaining the Certificate of Confidentiality can be found at http://grants.nih.gov/grants/policy/coc/appl_intramural.htm
24.0 INTERNATIONAL RESEARCH
A TTUHSC IRB shall review all research involving human subjects conducted under the auspices of TTUHSC regardless of the research location, including research conducted in foreign countries. When reviewing an international proposal, the IRB must be aware of the local research context (see Section 4.0). The IRB shall review translations of all relevant research documents (including informed consent, recruitment materials, and questionnaires, etc.) for accuracy. Protections afforded to subjects participating in research in a foreign county must approximate the protections provided to subjects in the United States. Requests to review and modify standard elements of domestic approvals may be considered by the IRB. The TTUHSC IRB should make every attempt to have documents reviewed by a consultant from the targeted country for accuracy of translation and to assure that no local norms in the foreign country are being violated.
25.0 HUMAN IMMUNODEFICIENCY VIRUS (HIV) REPORTING REQUIREMENTS

HIV Testing
PIs at TTUHSC and all its affiliates must comply fully with all applicable Federal and State laws, including those concerning notification of HIV serostatus. Individuals whose test results are associated with personal identifiers must be informed of their own test results and provided the opportunity to receive appropriate counseling. This information may also be reported to government entities as required by law. Potential subjects must be made aware of this notification. Persons obtaining consent should inform the subjects and this information must be included in the informed consent form.
26.0 RESEARCH COMPLIANCE

The IRB and EVPR are authorized to monitor human subjects research approved by the IRB pursuant to the responsibilities and assurances made by TTUHSC under federal regulations (FWA 00006767) and TTUHSC policy (TTUHSC OP 73.06). The RIO shall be responsible for compliance activities on behalf of the IRB and EVPR, including audits and monitoring of IRB approved research.

26.1 IRB Authority

The IRB has the authority to inspect research facilities, obtain records and other relevant information relating to the use of human subjects in research. The IRB takes such actions that are in its judgment necessary to enforce compliance with applicable federal and state law, regulations, or guidelines, including action to suspend/terminate approval of research that is not being conducted in accordance with IRB requirements or that has been associated with unexpected serious harm to subjects (TTUHSC OP 73.06).

The IRB has the authority to observe or appoint a designee to observe the informed consent process and IRB approved research activities [(45 CFR 46.109(e)].

The IRB may determine that some research projects require verification from sources other than the PI to confirm that no unapproved changes have occurred since the previous IRB review. The IRB may direct verification through the use of audits of research records, inquiries, and/or observing the informed consent process and conduct of the research. The IRB, EVPR, RIO, and/or authorized TTUHSC officials have authority to audit research studies reviewed by a TTUHSC IRB.

26.2 Monitoring and Audits

The EVPR is responsible for the development and implementation of a research compliance program at TTUHSC. The Research Integrity Office has been established by the EVPR to provide administrative support to the IRB and to maintain research compliance at TTUHSC with applicable laws, regulations, and TTUHSC policy.

The PI shall make available all research records for review or audit upon request of the IRB, the EVPR, and RIO or authorized designee. Routine compliance audits shall be conducted as part of the monitoring process. Special audits may also be conducted on behalf of the IRB at the request of the IRB Chair, Director of RIO and/or the EVPR in response to allegations that research is not being conducted in accordance with IRB requirements or has been associated with unexpected serious harm to subjects or others.

Monitoring and/or auditing activities may include, but are not limited to the following:

• Study file for required elements including the presence of required documentation; protocol and amendments; approved consent forms and IRB documentation
• Subject eligibility
• Informed Consent Documentation
• Unanticipated and Adverse Event reporting
• Accuracy and completeness of Case Report Forms
• Confidentiality of records

REVISION October, 2011 - 71 -
• Drug and Device handling and accountability
• Laboratory data
• Concomitant medications/therapy
• Subject history
• Progress reports from PIs
• Contact research subjects
• Audit advertisements and other recruiting materials as deemed appropriate by the IRB
• Other Research conducted by PIs
• Other monitoring or auditing activities deemed appropriate by the IRB
• Any additional information determined necessary by the EVPR.

Allegations of Non Compliance or Harm to Subjects
The Research Integrity Office (RIO) shall document the receipt of allegations of non-compliance with IRB approved protocol or harm to research subjects or others. Information received by the RIO shall be reviewed in a timely manner and assigned to research compliance personnel for audit pursuant to criteria and procedures established in the TTUHSC Research Compliance Office Procedure Manual or through procedures outlined in HSC OP 73.07 (Research Misconduct) if the allegation involves fabrication, falsification or plagiarism. Audit findings and reports will be sent to the PI, IRB Chair, RIO Director and EVPR. The IRB may report findings of non-compliance or IRB decisions to the PIs direct supervisor or others as it deems necessary.

The IRB Chair will determine the need for full IRB review of audit reports. The report may be placed on the agenda of the next regularly scheduled meeting for notification or discussion, as appropriate. The Full Board may vote to suspend/terminate the research if it is found that a human subject has been exposed to unexpected serious harm or that research is not being conducted in accordance with IRB approved protocol. In addition if the EVPR concludes that the research does not fully comply with policies or obligations of TTUHSC, the research may be disapproved, or suspended/terminated on behalf of TTUHSC.

Compliance reports summarizing all IRB compliance activities including audits shall be submitted to each IRB and EVPR by the RIO on a pre-determined schedule. Compliance reports are confidential and privileged Medical Committee documents.

26.3 Research Without IRB Approval

If research is or has been conducted by TTUHSC faculty, staff, or students without IRB approval, any person with knowledge about this shall immediately report it to the EVPR and/or the local IRB. Corrective steps will be taken to ensure that the researcher is aware of all federal, state, and local policies and procedures. Researchers will be asked to immediately stop all research and inform any journals, meetings, etc. where research was presented or where presentation is pending that the research was conducted without IRB approval.

26.4 External Audits

Federal Regulatory Agency
PI shall notify RIO Research Compliance Officer immediately upon receipt of impending notice of audit or investigation.
Sponsor Monitoring Reports
Investigators shall send a copy of external sponsor monitoring reports to the Research Compliance Officer within 5 days of receipt.
APPENDIX A – GLOSSARY OF TERMS

ADMINISTRATIVELY CLOSED  Decision of the IRB based on PI non-responsiveness to IRB requests. This can occur prior to initial IRB approval or any time following IRB approval.

ADVERSE EVENT (AE)  Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research. Also see: Internal Adverse Event; External adverse event; Unanticipated Adverse Event; Unanticipated Problem; Serious Adverse Event.

APPROVED  The IRB has reviewed the study and made a determination that the study has met all requirements. Subjects may be enrolled in the study.

ASSENT  Agreement by an individual not competent to give legally valid informed consent (e.g., a child or cognitively impaired person) to participate in research. Mere failure to object to the research may not be construed as assent.

AUDIT  A systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data were recorded, analyzed, and accurately reported according to the protocol, sponsor’s standard operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory requirement(s).

AUTHORIZED OFFICIAL  An officer of an entity with the authority to speak for and legally commit the entity to comply with requirements of the federal regulations regarding the involvement of human subjects in biomedical and behavioral research.

AUTONOMY  Personal capacity to consider alternatives, make choices, and act without undue influence or interference of others.

BELMONT REPORT  A statement of basic ethical principles governing research involving human subjects issued by the National Commission for the Protection of Human Subjects in 1978.

BENEFIT  A valued or desired outcome; an advantage.

BIOLOGIC  Any therapeutic serum, toxin, anti-toxin or analogous microbial produce applicable to the prevention, treatment, or cure of diseases or injuries.

BENEFICENCE  An ethical principle discussed in the Belmont Report that entails an obligation to protect persons from harm. The principle of beneficence can be expressed in two general rules: (1) do not harm; and (2) protect from harm by maximizing possible benefits and minimizing possible risks of harm.

CASE REPORT FORM (CRF)  A printed, optical, or electronic document designed to record all of the protocol-required information to be reported to the sponsor on each trial subject.

CHILDREN  Persons who have not attained the legal age for consent to treatment or
procedures involved in the research, as determined under the applicable law of the jurisdiction
in which the research will be conducted [45 CFR 46.401(a)].

**CLINICAL TRIAL** A research study to answer specific questions about vaccines or new
therapies or new ways of using known treatments. Clinical trials are used to determine whether
new drugs or devices are safe and/or effective. Carefully conducted clinical trials are the
fastest and safest way to find treatments that work in people.

**CLOSURE** See Study Closure

**COGNITIVELY IMPAIRED** Legally competent persons who may be compromised in any way in
their ability to make decisions in their best interests.

**COMPETENCE** A legal term used to denote capacity to act on one’s own behalf; the ability to
understand information presented, to appreciate the consequences of acting (or not acting) on
that information, and to make a choice. (See also: Incompetence, Incapacity.)

**COMPLIANCE** Adherence to all the trial-related requirements, good clinical practice (GCP)
requirements, and the applicable regulatory and institutional requirements.

**CONFIDENTIALITY** The treatment of information that an individual has disclosed in a
relationship of trust and with the expectation that it will not be divulged to others without
permission in ways that are inconsistent with the understanding of the original disclosure.

**CONFLICT OF INTEREST COMMITTEE** See TTUHSC OP 73.09. The Conflict of Interest
Committee is appointed by the EVPR to review and oversee the management of financial
conflicts of interest in research.

**CONSENT** See: Informed Consent.

**CONTINUING REVIEW** Periodic review of a research study by an IRB to evaluate whether
risks to participants are reasonable in relation to potential benefits and to verify that the study
continues to meet regulatory and institutional requirements. Continuing review shall be
conducted at intervals appropriate to the degree of risk but not less than once per year. (45CFR
46.109(e)); 21 CFR 56.109(f))

**CONTRACT** An agreement; as used here, an agreement that a specific research activity will
be performed at the request, and under the direction, of an entity providing funds. Research
performed under the contract is more closely controlled by the entity than research performed
under a grant.

**DATA SAFETY MONITORING BOARD** A committee of scientists, physicians, statisticians, and
others that collects and analyzes data during the course of a clinical trial to monitor for adverse
effects and other trends (such as an indication that one treatment is significantly better than
another, particularly when one arm of the trial involves a placebo control) that would warrant
modification or termination of the trial or notification of subjects about new information that might
affect their willingness to continue in the trial.

**DE-IDENTIFIED** no information is linked to the specimen that would allow the investigator to
identify the donor and no attempts will be made by the investigator to identify the donor using
genetic analysis technology, detailed demographic/clinical parameter matching or other means.
DEVICE (MEDICAL)  A diagnostic or therapeutic article that does not achieve any of its principal intended purpose through chemical action within or on the body. Such devices include diagnostic test kits, crutches, electrodes, pacemakers, arterial grafts, intraocular lenses, and orthopedic pins or other orthopedic equipment.

DHHS  A federal agency: U.S. Department of Health and Human Services; the Office of Human Research Protection (OHRP) and the Food and Drug Administration (FDA) are agencies of DHHS.

DISAPPROVED  The IRB has reviewed the study and determined that it is not approved and may not receive further review. See also Request for Reconsideration

DOCUMENTATION  All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records; and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken.

DRUG  Any chemical compound that may be used on or administered to humans as an aid in the diagnosis, treatment, cure, mitigation, or prevention of disease or other abnormal conditions.

ENTITY  An organization, institution or being that has its own existence for legal or tax purposes, is legally separate from TTUHSC, and possess OHRP-approved Assurances and IRB Agreements with TTUHSC.

EXEMPT RESEARCH  Research determined by person(s) designated by the Research Integrity Office to involve human subjects in one or more of certain minimal risk categories [38 CFR 16.101(b)].

EXISTING  Data or specimens already have been collected and stored at the time the research is proposed to the IRB for a determination of whether the research is exempt. Material collected after the date of the initial submission to IRB is not "existing" for purposes of this policy.

EXTERNAL ADVERSE EVENT  Adverse events experienced by subjects enrolled by investigators at other sites participating in the same clinical trial as investigators at TTUHSC/Affiliates.

EQUITABLE  Fair or just; used in the context of selection of subjects to indicate that the benefits and burdens of research are fairly distributed.

EXPEDITED REVIEW  Review of proposed research by the IRB chair or a designated voting member or group of voting members rather than by the entire IRB. Federal rules permit expedited review for certain kinds of research involving no more than minimal risk and for minor changes in approved research.

EXPERIMENTAL  Term often used to denote a therapy (drug, device, procedure) that is unproven or not yet scientifically validated with respect to safety and efficacy. A procedure may be considered "experimental" without necessarily being part of a formal study (research) to evaluate its usefulness.
FDA  Food and Drug Administration; an agency of the federal government established by Congress in 1912 and presently part of the Department of Health and Human Services.

FEDERALWIDE ASSURANCE (FWA)  An agreement between a federally funded entity and OHRP that stipulates methods by which the entity will protect research participants (66 Fed Reg 19139, 19141(April 13, 2001)

FETUS  The product of conception from implantation until delivery [45 CFR 46.202].

FULL BOARD REVIEW  Review of proposed research at a convened meeting at which a majority of the voting membership of the IRB is present, including at least one member whose primary concerns are in nonscientific areas. For the research to be approved, it must receive the approval of a majority of those voting members present at the meeting.

GRANT  Financial support provided for research study designed and proposed by the Principal Investigator(s). The granting agency exercises no direct control over the conduct of approved research supported by a grant.

GUARDIAN  An individual who is authorized under applicable state or local law to give permission on behalf of another to general medical care [45 CFR 46.402(3)]

HIPAA  Health Insurance Portability and Accountability Act of 1996

HUMAN SUBJECTS  Individuals whose physiologic or behavioral characteristics and responses are the object of study in a research project. Under the federal regulations, human subjects are defined as: living individual(s) about whom an investigator conducting research obtains: (1) data through intervention or interaction with the individual; or (2) identifiable private information.

IDE  See: Investigational Device Exemptions.

IDENTIFIER  a piece of information that identifies a specific person or that could be used to identify a specific person. For purposes of human research, names, codes linked to names, social security numbers, patient ID numbers and other such commonly-used data elements are considered identifiers. However the Health Insurance Portability and Accountability Act (HIPAA) definition is broader, including a specific list of data elements

IND  See: Investigational New Drug.

IND SAFETY REPORT  See: External Adverse Event.

INFORMED CONSENT  A person's voluntary agreement, based upon adequate knowledge and understanding of relevant information, to participate in research or to undergo a diagnostic, therapeutic, or preventive procedure. In giving informed consent, subjects may not waive or appear to waive any of their legal rights, or release or appear to release the investigator, the sponsor, the entity or agents thereof from liability for negligence.

INSTITUTIONAL REVIEW BOARD (IRB)  A specially constituted review body established or designated by an entity to protect the welfare of human subjects recruited to participate in
biomedical or behavioral research. At TTUHSC, the IRB is deemed to be a medical committee.

**INTERNAL ADVERSE EVENT** Any adverse events experienced by a single subject enrolled in TTUHSC or TTUHSC IRB affiliate research project.

**INVESTIGATIONAL DEVICE EXEMPTION (IDE)** An unapproved medical device that is used to save the life of a patient or to help a patient suffering from a serious disease or condition for which there no other alternative therapy exists. Patients/physicians faced with these circumstances may have access to investigational devices under one of four main mechanisms by which FDA may make an unapproved device available: Emergency Use, Compassionate Use (or Single Patient/Small Group Access), Treatment Use, or Continued Access.

**INVESTIGATIONAL NEW DRUG OR DEVICE (IND)** A drug or device permitted by FDA to be tested in humans but not yet determined to be safe and effective for a particular use in the general population and not yet licensed for marketing.

**INVESTIGATIONAL PRODUCT** A device or pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.

**INVESTIGATOR’S BROCHURE** A compilation of the clinical and nonclinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human subjects.

**IRB** See: Institutional Review Board.

**IRB RECORDS** IRB records include but are not limited to: all minutes of IRB meetings, a copy of all proposals reviewed including all amendments, investigator brochures, and any supplemental information including recruitment and informational materials, consent forms, information submitted for continuing review, all correspondence, and IRB membership with a resume for each member.

**iRIS** Internet Medical Research Information System—the software through which all IRB applications, reviews and approvals are submitted and through which information is communicated between investigators and the IRB.

**JUSTICE** An ethical principle discussed in the Belmont Report requiring fairness in distribution of burdens and benefits; often expressed in terms of treating persons of similar circumstances or characteristics similarly.

**MINIMAL RISK** The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in the participant's daily life or during the performance of routine physical or psychological examinations or tests [45 CFR 46.102(i); 21 CFR 50.3(k)]. In research involving prisoners, minimal risk is also defined as the probability and magnitude of physical or psychological harm that is normally encountered in the daily lives, or in the routine medical, dental, or psychological examination of healthy persons. [45 CFR 46.303(d)].
MONITORING  The collection and analysis of data as the project progresses to assure the appropriateness of the research, its design and subject protections.

NONAFFILIATED MEMBER  Member of an Institutional Review Board who has no ties to the parent entity, its staff, or faculty. This individual is usually from the local community (e.g., minister, business person, attorney, teacher, homemaker).


PERMISSION  Parent(s) or guardian’s written agreement to the participation of their child or ward in research.

PREGNANCY  The period of time from implantation until delivery. A woman shall be assumed to be pregnant if she exhibits any of the pertinent presumptive signs of pregnancy, such as missed menses, until the results of a pregnancy test are negative or until delivery [45 CFR 46.202].

PRINCIPAL INVESTIGATOR (PI)  The scientist or scholar with ultimate responsibility for the design and conduct of a research project.

PRISONER  Prisoners are any individuals involuntarily confined or detained in a penal institution. It includes persons who are detained pending arraignment, trial, or sentencing, and persons who become prisoners after research has begun.

PRIVACY BOARD  IRB or another review body which reviews requests to use or disclose Private Health Information (PHI) for research purposes without authorization under HIPAA.

PROSPECTIVE STUDIES  Studies designed to observe outcomes or events that occur subsequent to the identification of the group of subjects to be studied. Prospective studies need not involve manipulation or intervention but may be purely observational or involve only the collection of data.

PROTOCOL  The formal design or plan of an experiment or research activity; specifically, the plan submitted to an IRB for review and to an agency for research support. The protocol includes a description of the research design or methodology to be employed, the eligibility requirements for prospective subjects and controls, the treatment regimen(s), and the proposed methods of analysis that will be performed on the collected data.

PROTOCOL DEVIATION  Unplanned or unforeseen change in the implementation of an IRB-approved protocol Protocol deviations must be reported to the IRB.

QUORUM  A majority of the voting members appointed to the IRB membership. A quorum must include at least one member whose primary concerns are in non-scientific areas. A quorum must be established, recorded, and maintained for the deliberation and vote on all matters requiring a vote.

REPRESENTATIVE  A person who makes decisions on behalf of another person. In human subjects research, an individual or judicial or other body may be authorized to consent on behalf
of a prospective subject to the subject's participation in the procedure(s) involved in the research.

**REQUEST FOR ADDITIONAL INFORMATION**  A request made by the IRB for changes or clarifications to studies it has reviewed.

**RESEARCH** Systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge [45 CFR 102(d)].

**RESEARCH INTEGRITY OFFICE (RIO)** Office responsible for the oversight and direction of the human research protection program at TTUHSC, which includes administrative oversight of the IRB, the TTUHSC Research Compliance Program, and TTUHSC Educational requirements for human research.

**RESPECT FOR PERSONS** An ethical principle discussed in the Belmont Report requiring that individual autonomy be respected and that persons with diminished autonomy be protected.

**RETROSPECTIVE STUDIES** Research conducted by reviewing records which are already in existence at the time the research begins.

**REVIEW (OF RESEARCH)** The oversight of research on a periodic basis by the IRB. In addition to the at least annual reviews mandated by the federal regulations, reviews may, if deemed appropriate, also be conducted on a continuous or periodic basis.

**RISK** The probability of harm or injury (physical, psychological, social, or economic) occurring as a result of participation in a research study. Both the probability and magnitude of possible harm may vary from minimal to significant. Federal regulations define only "minimal risk".

**SECONDARY USE** a purpose other than that for which data or a specimen originally was collected.

**SERIOUS ADVERSE EVENT (SAE)** Any adverse event temporally associated with the subject's participation in research that meets any of the following criteria:
(1) results in death;
(2) is life threatening (Places the subject at immediate risk of death from the event as it occurred);
(3) requires inpatient hospitalization (for a person not already hospitalized) or prolongation of hospitalization (for a subject already hospitalized);
(4) results in persistent or significant disability or incapacity;
(5) results in congenital anomaly and/or birth defects;
(6) an event that jeopardizes the subject's health and may require medical or surgical treatment to prevent one of the preceding outcomes.

**SPECIMEN** any biological material obtained from or derived from patients or human research subjects. This includes, but is not limited to: fixed, frozen or fresh pathology or autopsy specimens; blood; urine; saliva; CSF; semen; breast milk; and any purified DNA, RNA, proteins, cell lines or clones.

**SPONSOR** A person or other entity that initiates a clinical investigation, but that does not actually conduct the investigation, i.e., the test article is administered or dispensed to, or used involving, a subject under the immediate direction of another individual. A person other than an
individual (e.g., a corporation or agency) that uses one or more of its own employees to conduct an investigation that it has initiated is considered to be a sponsor (not a sponsor-investigator) and the employees are considered to be investigators.

**STUDY**  All components of a research project.

**STUDY CLOSURE**  Study approved by the IRB that may be closed by the investigator, the sponsor, the IRB, TTUHSC, or by an affiliated entity. (See: Section 17)

**SUSPENSION/TERMINATION**  IRB approval is suspended/terminated and all research activity halted as the result of unanticipated problems involving risks to subjects or others; serious or continuing noncompliance with 45 CFR Part 46; or the requirements or determinations of the IRB. Requires prompt reporting to federal regulatory authorities and TTUHSC pursuant to federal Assurance and 45 CFR Part 46.

**SURVEY**  Studies designed to obtain information from a large number of respondents through written questionnaires, telephone interviews, door-to-door canvassing, or similar procedures.

**TABLED**  The IRB has reviewed the study and determined that extensive changes are necessary. The study will be re-reviewed at a convened meeting of the IRB once changes have been made.

**UNANTICIPATED ADVERSE DEVICE EFFECTS**  Adverse effects that occur with unlicensed devices approved by the FDA for research. These are reported directly to the IRB.

**UNANTICIPATED PROBLEM**  Any incident, experience, or outcome that meets all of the following criteria:
1. events are not expected given (a) the nature of the research procedures and (b) the characteristics of the subject population being studied; AND
2. related or possibly related to a subject’s participation in the research; AND
3. suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) related to the research than was previously known or recognized.

**UNEXPECTED ADVERSE EVENT**  Any adverse event occurring in one or more subjects in a research protocol, the nature, frequency, or severity of which is not consistent with either:

1. the known of foreseeable risk of adverse events associated with the procedures involved in the research that are described in (a) the protocol-related documents, such as the IRB-approved research protocol, any applicable investigator brochure, and the current IRB-approved informed consent document, and (b) other relevant sources of information, such as product labeling and package inserts; or
2. the expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject’s predisposing risk factor profile for the adverse event.

**VOLUNTARY**  Free of coercion, duress, or undue inducement. Used in the research context to refer to a subject's decision to participate (or to continue to participate) in a research activity